: The AMEDEO Literature Guide

Home The Word Brain

My Amedeo

FAQ

Privacy

About

Amedeo C49

English + 你好 (nǐ hǎo) = limitless possibilities.
Start learning Mandarin Chinese today—for free, forever.

Amedeo C49 is completely free, for life. Next week: +49.

Gynecology

Free Subscription

Articles published in Gynecol Oncol
Retrieve available abstracts of 418 articles:
HTML format

Single Articles

July 2025

HARDESTY MM, Krivak TC, Wright GS, Hamilton E, et al
A phase 2 trial of niraparib plus bevacizumab maintenance therapy following first-line platinum-based chemotherapy with bevacizumab in advanced ovarian cancer: final analysis and overall survival results from OVARIO.
Gynecol Oncol. 2025;199:96-102.
PubMed Abstract available

June 2025

RANDALL L, Xiang Y, Matsumoto T, Giannarelli D, et al
Patient-reported outcomes from the phase 3, randomized, double-blind, placebo-controlled ENGOT-cx11/GOG-3047/KEYNOTE-A18 study of pembrolizumab plus concurrent chemoradiotherapy in participants with high-risk locally advanced cervical cancer.
Gynecol Oncol. 2025;199:88-95.
PubMed Abstract available

LINDEMANN K, Berton D, Sehouli J, Christensen RD, et al
NSGO-FANDANGO/ENGOT-EN1: A randomized phase II study of first-line combination chemotherapy with nintedanib/placebo in advanced/recurrent endometrial cancer.
Gynecol Oncol. 2025;199:79-87.
PubMed Abstract available

DZYUBAK O, Glass K, Watts M, Tarafdar O, et al
Oncologic and fertility outcomes of progestin therapy for atypical hyperplasia and grade 1 cancer of the endometrium: Results of a specialized oncofertility program.
Gynecol Oncol. 2025;199:72-78.
PubMed Abstract available

GREENMAN M, Bellone S, Demirkiran C, Hartwich TMP, et al
Datopotamab deruxtecan, a novel TROP2-tareting antibody-drug conjugate with a topoisomerase I inhibitor payload, shows preclinical activity against primary and metastatic uterine and ovarian TROP2 over-expressing carcinosarcoma.
Gynecol Oncol. 2025;199:64-71.
PubMed Abstract available

WANG M, Dong T, Lucero M, Pan W, et al
Association between glucagon-like peptide-1 receptor agonists and ovarian cancer survival: A population-based cohort study.
Gynecol Oncol. 2025;199:57-63.
PubMed Abstract available

CHAN JK, Tewari K, Monk BJ, Herzog TJ, et al
Optimizing therapy for cervical cancers - Translating trial data into clinical decision-making.
Gynecol Oncol. 2025;199:47-50.
PubMed

KAHVECIOGLU A, Gultekin M, Yigit E, Sari SY, et al
Adjuvant radiotherapy outcomes and prognostic factors in FIGO 2023 stage IIC endometrial cancer: One sea, different depths.
Gynecol Oncol. 2025;199:40-46.
PubMed Abstract available

VARGIU V, Rosati A, Santullo F, Figa M, et al
REACT bowel REcovery after CyToreductive surgery for advanced ovarian cancer.
Gynecol Oncol. 2025;199:32-39.
PubMed Abstract available

LIU Y, Zhou Y, Zhou Z, Rao X, et al
GTN misdiagnosed as ectopic pregnancy: a 17-year retrospective cohort study.
Gynecol Oncol. 2025;199:27-31.
PubMed Abstract available

WEI TY, Wu CC, Hsu YT, Lin WH, et al
An exploratory analysis of driver gene alterations and their potential prognostic relevance in endometrial cancer with POLE exonuclease domain mutations.
Gynecol Oncol. 2025;199:17-26.
PubMed Abstract available

BIANCHI T, Grassi T, De Ponti E, Jaconi M, et al
Fertility sparing surgery in patients with advanced borderline ovarian tumors: Oncologic outcomes of a single-institution cohort.
Gynecol Oncol. 2025;199:10-16.
PubMed Abstract available

HUEPENBECKER SP, Iniesta MD, Munsell MF, Mandayam S, et al
No increase in chronic kidney disease after postoperative acute kidney injury in gynecologic oncologic ERAS surgery.
Gynecol Oncol. 2025;198:168-175.
PubMed Abstract available

DAMIAN FB, De Melo AC, Dal Molin GZ, Nogueira-Rodrigues A, et al
A phase II trial of palbociclib plus letrozole after progression on second-line chemotherapy for women with hormone receptor-positive high-grade serous or endometrioid ovarian, fallopian tube, or peritoneal cancer (LACOG 1018).
Gynecol Oncol. 2025;198:161-167.
PubMed Abstract available

VINTZILEOS W, Beer H, Sunkara Y, Pruszynski J, et al
Prognostic indicators of recurrence and treatment-free interval in uterine carcinosarcoma.
Gynecol Oncol. 2025;198:154-160.
PubMed Abstract available

BOUAZZI M, Zheng G, Wang J, Baandrup L, et al
Use of statins and risk of ovarian cancer: evidence on effect modification by parity, menopause and endometriosis from nationwide nested case-control studies.
Gynecol Oncol. 2025;198:130-136.
PubMed Abstract available

MATSUO K, Friedman EL, Lee MW, Masjedi AD, et al
Cytology-negative, non-myoinvasive stage IC serous endometrial cancer: Assessment of adjuvant chemotherapy omission.
Gynecol Oncol. 2025;198:146-153.
PubMed Abstract available

NGUYEN JMV, Zigras T, Gayowsky A, Marcucci M, et al
Association of frailty with perioperative and survival outcomes in patients with gynecologic cancers: A population-based study.
Gynecol Oncol. 2025;198:137-145.
PubMed Abstract available

FU Z, Borho L, Taylor SE, Kelemen LE, et al
Ovarian cancer risk and survival according to tumor sex hormone receptor expression: An ovarian Cancer association consortium and ovarian tumor tissue analysis consortium pooled analysis.
Gynecol Oncol. 2025;198:112-129.
PubMed Abstract available

MELO V, Vanegas G, O'Riordan DL, Kuruvilla P, et al
A population health approach to assessing for and addressing palliative care needs in outpatients with advanced gynecologic malignancies.
Gynecol Oncol. 2025;198:104-111.
PubMed Abstract available

INIESTA MD, Ramirez PT, Munsell MF, Basabe S, et al
Integration of self-hypnosis in an enhanced recovery after surgery program in gynecologic oncology - A prospective randomized trial.
Gynecol Oncol. 2025;198:96-103.
PubMed Abstract available

RING KL, Mills AM, Howitt BE, Grisham RN, et al
Mesonephric-like adenocarcinoma of the female genital tract: Pathologic diagnosis, clinical outcomes, and novel therapeutics.
Gynecol Oncol. 2025;197:57-65.
PubMed Abstract available

KURNIT KC
The search for new therapeutic options for uterine carcinosarcoma.
Gynecol Oncol. 2025;197:A1-A2.
PubMed

May 2025

KISTENFEGER Q, Haight PJ, Levine M, Wang H, et al
The impact of antibiotics, proton pump inhibitors, H2-receptor antagonists, and steroids on survival in ovarian cancer patients receiving PARP inhibitor therapy.
Gynecol Oncol. 2025;198:90-95.
PubMed Abstract available

CHO WK, Park W, Kim SW, Lee KK, et al
Postoperative hypofractionated intensity-modulated radiation therapy in cervical cancer: prospective phase 2 trial (POHIM_RT study).
Gynecol Oncol. 2025;198:84-89.
PubMed Abstract available

PHAM ENB, van den Berg CB, Kokke NCCJ, van Marion R, et al
Molecular diversity in uterine carcinosarcoma: Beyond TP53.
Gynecol Oncol. 2025;198:75-83.
PubMed Abstract available

IIDA Y, Churchman M, Hollis RL, Taylor S, et al
Combined genomic and molecular analysis defines prognostic markers of relapse in stage IA-IC1 clear cell ovarian carcinoma.
Gynecol Oncol. 2025;198:66-74.
PubMed Abstract available

LAM C, Zhou Q, Aghajanian C, Abu-Rustum NR, et al
Prognostic significance of estrogen receptor expression and estrogen signaling in endometrial carcinomas of no specific molecular profile: A comprehensive molecular and pathologic analysis.
Gynecol Oncol. 2025;198:59-65.
PubMed Abstract available

EHIMIAGHE E, Marjon N, Post MD, Corr BR, et al
The evolving role of HER2 in gynecologic oncology and clinical trial design: A gynecologic pathologist's perspective.
Gynecol Oncol. 2025;198:55-58.
PubMed

ACOSTA U, Bebia V, Torne A, Carreras-Dieguez N, et al
Topographic mapping of pelvic and aortic lymph node metastases in stage IIIC1r locally advanced cervical cancer: A retrospective study by the Spain-GOG group.
Gynecol Oncol. 2025;198:49-54.
PubMed Abstract available

NEWELL A, Andac-Jones E, Gonzalo M, Wright AA, et al
Patients with advanced ovarian cancer and their experiences and perceptions of sleep disturbance and fatigue across the treatment trajectory: A qualitative study.
Gynecol Oncol. 2025;198:42-48.
PubMed Abstract available

YANG W, Shen Y, Tian Y, Xiao X, et al
Evaluation of mutations detected in uterine exfoliated cells as a diagnostic tool for endometrial cancer.
Gynecol Oncol. 2025;198:33-41.
PubMed Abstract available

LEE JY, Boonyapipat S, Yuan G, Kim HS, et al
AdvanTIG-202: Phase 2 open-label, two-cohort multicenter study of ociperlimab plus tislelizumab and tislelizumab alone in patients with previously treated recurrent or metastatic cervical cancer.
Gynecol Oncol. 2025;198:25-32.
PubMed Abstract available

GU J, Zheng W, Li F, Luo C, et al
Redefining stage IVB cervical cancer: The unique prognosis of distant lymph node metastasis which is comparable to stage IIIC.
Gynecol Oncol. 2025;198:17-24.
PubMed Abstract available

BERG HF, Trovik J, Hjelmeland ME, Lien HE, et al
Pragmatic preoperative molecular classification of endometrial cancers; Replacing POLE sequencing with hormone receptor staining.
Gynecol Oncol. 2025;198:9-16.
PubMed Abstract available

LEE EK, Xiong N, Krasner C, Polak M, et al
Phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient recurrent or persistent endometrial cancer.
Gynecol Oncol. 2025;198:1-8.
PubMed Abstract available

WAGAR MK, Reetz E, Huang D, Kao MJ, et al
Patterns of primary metastasis and recurrence in mismatch repair deficiency and p53 abnormal endometrial carcinoma.
Gynecol Oncol. 2025;197:171-178.
PubMed Abstract available

WAGGONER RM, Mahoney RP, Nathan D, Zell JA, et al
Assessing preventive gynecologic decisions in individuals with Lynch syndrome.
Gynecol Oncol. 2025;197:163-170.
PubMed Abstract available

BYRNE ME, Selenica P, Dessources K, Da Cruz Paula A, et al
Peritoneal washings analysis in endometrial cancer: Comparison of somatic mutation detection with panel sequencing and traditional cytology.
Gynecol Oncol. 2025;197:155-162.
PubMed Abstract available

XIAO Y, Pang J, Zhou Y, Lu J, et al
FRalpha expression in advanced endometrial carcinoma: Clinicopathological, molecular, and prognosis correlates.
Gynecol Oncol. 2025;197:146-154.
PubMed Abstract available

EVANS E, Dholakia J, Abraham J, Hinton A, et al
Whole-exome sequencing provides assessment of homologous recombination deficiency for identification of PARPi-responsive ovarian tumors.
Gynecol Oncol. 2025;197:139-145.
PubMed Abstract available

MOUFARRIJ S, Dopeso H, Brown DN, Green H, et al
TROP2 expression and therapeutic targeting in uterine carcinosarcoma.
Gynecol Oncol. 2025;197:129-138.
PubMed Abstract available

KARLSSON E, Vorobii O, Silins I, Sundstrom Poromaa I, et al
Splenectomy as an indicator for ovarian cancer spread and complete cytoreduction.
Gynecol Oncol. 2025;197:121-128.
PubMed Abstract available

KEVERLINE KJ, Hill B, Hom-Tedla M, Jacobs M, et al
Impact of mismatch repair (MMR) status on recurrence in high intermediate risk endometrial cancer.
Gynecol Oncol. 2025;197:116-120.
PubMed Abstract available

ETTORRE VM, Bellone S, Greenman M, McNamara B, et al
A phase 2 trial of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability (NCT02899793): Updated survival and response analyses.
Gynecol Oncol. 2025;197:110-115.
PubMed Abstract available

SUH-BURGMANN E, Hung YY, Finertie H, Zhong H, et al
Association of endometrial cancer epigenetic mismatch repair deficiency with clinicopathologic factors and survival in a large, diverse community-based cohort.
Gynecol Oncol. 2025;197:102-109.
PubMed Abstract available

THAKER PH, Richardson DL, Hagemann AR, Holloway RW, et al
OVATION-2: A randomized phase I/II study evaluating the safety and efficacy of IMNN-001 (IL-12 gene therapy) with neo/adjuvant chemotherapy in patients newly-diagnosed with advanced epithelial ovarian cancer.
Gynecol Oncol. 2025 May 2:S0090-8258(25)00797.
PubMed Abstract available

ALIMENA S, Reid H, Bercow A, Feltmate C, et al
Trends in sentinel lymph node evaluation for vulvar melanoma in the United States from 2012 to 2018.
Gynecol Oncol. 2025;196:175-181.
PubMed Abstract available

CORNEL KMC, Mehta MP, Swift BE, Covens A, et al
The use of indocyanine green (ICG) for sentinel lymph node detection in vulvar cancer.
Gynecol Oncol. 2025;196:146-151.
PubMed Abstract available

STUEBS FA, Knoll A, Hartmann A, Matek C, et al
Trop2-expression in primary vulvar squamous cell carcinoma.
Gynecol Oncol. 2025;196:78-84.
PubMed Abstract available

April 2025

LOUKOVAARA M, Pasanen A, Butzow R
Molecular subgroup-specific prognostic value of semiquantitative lymphovascular space invasion in early-stage endometrioid endometrial cancer.
Gynecol Oncol. 2025;197:96-101.
PubMed Abstract available

BAE J, Kim U, Paik ES, Lim MC, et al
Oncologic outcomes of minimally invasive surgery vs. abdominal hysterectomy in patients with low-risk, early-stage cervical cancer: A retrospective analysis of KGOG 1028 data based on SHAPE trial eligibility criteria.
Gynecol Oncol. 2025;197:91-95.
PubMed Abstract available

JOHNSON CR, Aryasomayajula C, Francoeur AA, Stewart C, et al
Pathogenic germline variants among women with uterine cancer by ancestry: A commercial laboratory collaborative research registry study.
Gynecol Oncol. 2025;197:83-90.
PubMed Abstract available

POVEDA A, Lheureux S, Colombo N, Cibula D, et al
Maintenance olaparib monotherapy in patients with platinum-sensitive relapsed ovarian cancer without a germline BRCA1 and/or BRCA2 mutation: Final overall survival results from the OPINION trial.
Gynecol Oncol. 2025;197:74-82.
PubMed Abstract available

YOU B, Anderson C, Cecere SC, Carrot A, et al
Impact of adding the immune checkpoint inhibitor atezolizumab to first-line chemotherapy on progression-free survival in poor-prognosis ovarian cancer: A retrospective analysis from the IMagyn050 trial.
Gynecol Oncol. 2025;197:66-73.
PubMed Abstract available

FITZGERALD KJ, Konstantinopoulos P, Matulonis U, Liu J, et al
A phase I clinical trial of radiation therapy, durvalumab and tremelimumab in recurrent gynecologic cancer.
Gynecol Oncol. 2025;197:51-56.
PubMed Abstract available

LEON-CASTILLO A, Horeweg N, Peters EEM, Ter Haar N, et al
Pattern of recurrence of the molecular subgroups in stage I high-grade endometrial cancer.
Gynecol Oncol. 2025;197:43-50.
PubMed Abstract available

XIE J, Maguire FB, Hofer BM, Cooley JJP, et al
Disparities in hysterectomy-corrected endometrial cancer incidence trends by histologic subtype among racial/ethnic groups in California, 2012-2019.
Gynecol Oncol. 2025;197:34-42.
PubMed Abstract available

FRIEDMAN EL, Guo XM, Furey KB, Lee AJ, et al
Temporal trends of sentinel lymph node biopsy without lymphadenectomy at cervical cancer surgery.
Gynecol Oncol. 2025;196:182-191.
PubMed Abstract available

GRCEVICH L, Chuzhyk O, Giannini A, McGree ME, et al
Safety and feasibility of same day discharge for robotic hysterectomy and staging for endometrial cancer.
Gynecol Oncol. 2025;197:19-24.
PubMed Abstract available

WILKE RN, Wu CF, Kanbergs A, Bercow AS, et al
Disparities in facility-level adoption of minimally invasive interval debulking surgery for advanced ovarian cancer.
Gynecol Oncol. 2025;197:11-18.
PubMed Abstract available

RIOS-DORIA E, Parker EU, Kohrn BF, Pike M, et al
TP53 somatic evolution in the normal endometrium of Black and White individuals.
Gynecol Oncol. 2025;197:1-10.
PubMed Abstract available

MORRIS DH, Kosmacki A, Tolby L, Marx C, et al
Integration of a lifestyle modification intervention for women with overweight and obesity in a gynecologic oncology practice.
Gynecol Oncol. 2025;196:168-174.
PubMed Abstract available

BORCINOVA M, Kohler C, Nemejcova K, Zapardiel I, et al
Preoperative tumour size assessment in patients with early-stage cervical cancer: Final results of the SENTIX study.
Gynecol Oncol. 2025;196:160-167.
PubMed Abstract available

RAIMONDO D, Raffone A, Maletta M, Restaino S, et al
Hysterectomy or not for borderline ovarian tumor in menopause?
Gynecol Oncol. 2025;196:152-159.
PubMed Abstract available

ZELISSE HS, Snijders MLH, Groenendijk FH, Halfwerk JBG, et al
The prognostic potential of molecular subtypes including estrogen receptor status in endometrioid ovarian cancer.
Gynecol Oncol. 2025;196:137-145.
PubMed Abstract available

METTALA T, Joutsiniemi T, Huvila J, Hietanen S, et al
Genetic predictors of unexpected recurrence in low-risk endometrial cancer: A comprehensive genomic analysis reveals FGFR2 as a risk factor and a rare fatal POLE-mutated recurrence.
Gynecol Oncol. 2025;196:129-136.
PubMed Abstract available

HABLASE R, Steinke J, Aslam A, Jose R, et al
Anastomotic leakage in colorectal and ovarian cancer resections: A comparative cohort study.
Gynecol Oncol. 2025;196:121-128.
PubMed Abstract available

GONZALEZ-BOSQUET J, Shahi M, Yadav S, Kanwar N, et al
ECPPF stratification identifies occult high-risk subgroups in stage I, grade 1 or 2,
Gynecol Oncol. 2025;196:113-120.
PubMed Abstract available

COSGROVE CM, Suarez AA, Haight PJ, Villacres A, et al
Exploring endometrial cancer risk stratification by copy number assessment.
Gynecol Oncol. 2025;196:99-106.
PubMed Abstract available

KAHN RM, Murphy K, Patel T, Yeoshoua E, et al
Three-dimensional volumetric rendering on augmented reality headsets for ovarian cancer cytoreduction planning: A Memorial Sloan Kettering Cancer Center Team Ovary study.
Gynecol Oncol. 2025;196:107-112.
PubMed Abstract available

VARGIU V, Santullo F, Scambia G, Naldini A, et al
STOMA study SToma-leak ratio in advanced ovarian cancer surgery: Results of a restrictive policy on the use of protective stoMAs.
Gynecol Oncol. 2025;196:92-98.
PubMed Abstract available

BUJNAK AC, Greenberg D, Chang J, Tseng J, et al
Adjuvant treatment in stage I clear cell endometrial carcinoma: A population-based study of survival outcomes.
Gynecol Oncol. 2025;196:85-91.
PubMed Abstract available

WOLF B, Trantaki DS, Horn LC, Aktas B, et al
Preoperative conization in cervical cancer patients undergoing open abdominal radical hysterectomy: Results from a propensity-score matched study.
Gynecol Oncol. 2025;196:69-77.
PubMed Abstract available

WESTRICK AC, Bailey Z, Schlumbrecht M
Influence of residential segregation and health provider density on advanced stage endometrial cancer diagnoses.
Gynecol Oncol. 2025;196:62-68.
PubMed Abstract available

HAGHIGHAT R, Ozarowski AL, Liu YL, Frey MK, et al
MUTYH: Possibly another important gene in ovarian cancer?
Gynecol Oncol. 2025;196:59-61.
PubMed

CIOFFI R, Fruscio R, Sabetta G, Bergamini A, et al
Consolidation courses in low-risk gestational trophoblastic neoplasia and relapse rate: A MITO-9 retrospective study.
Gynecol Oncol. 2025;196:54-58.
PubMed Abstract available

CHAM S, Kumar A, Walter LC, Lichtman S, et al
Understanding frailty and the role of patient-centered care for older adults with gynecologic cancer.
Gynecol Oncol. 2025;196:42-53.
PubMed Abstract available

TA QD, Do C, Sharma K, Sorooshian HZ, et al
Reduced dosing of lenvatinib with pembrolizumab for advanced endometrial cancer.
Gynecol Oncol. 2025;196:36-41.
PubMed Abstract available

LEATH CA 3RD, Deng W, Mell LK, Richardson DL, et al
Incorporation of triapine (T) to cisplatin chemoradiation (CRT) for locally advanced cervical and vaginal cancer: Results from NRG-GY006, a phase III randomized trial.
Gynecol Oncol. 2025;195:122-133.
PubMed Abstract available

BRINK GJ, Groeneweg JW, van der Ploeg P, Jonges GN, et al
Signal transduction pathway activity in adult-type granulosa cell tumor samples.
Gynecol Oncol. 2025;195:6-11.
PubMed Abstract available

PODDER V, Slomovitz BM
Rethinking metformin in advanced endometrial cancer: Scientific humility, translational challenges, and the urgency for equity.
Gynecol Oncol. 2025;195:A1-A2.
PubMed

March 2025

LORUSSO D, Oaknin A, Borges GS, Damian F, et al
Cemiplimab plus peltopepimut-S vaccine in recurrent cervical cancer: A phase 2 clinical trial.
Gynecol Oncol. 2025;196:28-35.
PubMed Abstract available

XIE H, Sun L, Yao S, Tian X, et al
Therapeutically targeting endometrial cancer in preclinical models by ICAM1 antibody-drug conjugates.
Gynecol Oncol. 2025;196:16-27.
PubMed Abstract available

KIM J, Jang J, Lim MC, Kim MH, et al
Which factors predict the effectiveness of adjuvant treatment in patients with non-high-risk early-stage cervical cancer? Ancillary analysis of KGOG-1028.
Gynecol Oncol. 2025;196:10-15.
PubMed Abstract available

MATULONIS UA, Herrstedt J, Oza A, Mahner S, et al
ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety.
Gynecol Oncol. 2025;195:192-199.
PubMed Abstract available

BUJNAK AC, Solaru SA, Tewari K
Clinical applications of antibody drug conjugates for gynecologic malignancies: Review of available medicines and emerging therapeutics.
Gynecol Oncol. 2025;195:180-191.
PubMed Abstract available

ETHIER JL, Shephard C, Granados DP, Dutta N, et al
Comparative efficacy and safety of low-dose versus high-dose bevacizumab in ovarian cancer: An indirect treatment comparison.
Gynecol Oncol. 2025;196:1-9.
PubMed Abstract available

JOHANNET P, Flint M, Chui MH, Konner J, et al
Patient outcomes in advanced ovarian cancer treated with an anti-FOLR1 antibody-drug conjugate.
Gynecol Oncol. 2025;195:173-179.
PubMed Abstract available

LI Y, Wu M, Liu Q, Huang C, et al
Development and validation of an ovarian cancer risk assessment tool for first-degree relatives of patients in the Chinese population.
Gynecol Oncol. 2025;195:165-172.
PubMed Abstract available

LEE EK, Kolin DL, Matulonis UA, Erickson BK, et al
Diagnostic and therapeutic advances for HER2-expressing or amplified gynecologic cancers.
Gynecol Oncol. 2025;195:152-164.
PubMed Abstract available

DEMARI JA, Glassman D, Smith S, Darby JP, et al
Endometrial cancer somatic testing practice patterns among gynecologic oncologists.
Gynecol Oncol. 2025;195:149-151.
PubMed

SULLIVAN MW, Chui MH, Selenica P, Long Roche K, et al
Anaplastic carcinoma of the ovary: A single-institution experience and molecular analysis.
Gynecol Oncol. 2025;195:144-148.
PubMed Abstract available

DE BONDT D, Naslazi E, Jansen E, Kupets R, et al
Validating the predicted impact of HPV vaccination on HPV prevalence, cervical lesions, and cervical cancer: A systematic review of population level data and modelling studies.
Gynecol Oncol. 2025;195:134-143.
PubMed Abstract available

CARUSO G, Kumar A, Langstraat CL, McGree ME, et al
Racial/ethnic, socioeconomic, and healthcare access disparities in achieving textbook oncologic outcome in advanced ovarian cancer.
Gynecol Oncol. 2025;195:106-114.
PubMed Abstract available

SALINARO J, Singh K, Sands N, Gill V, et al
Distribution and concordance of HER2 scores in endometrial and ovarian cancer.
Gynecol Oncol. 2025;195:115-121.
PubMed Abstract available

ENGH A, Rueegg CS, Bjerre Trent PK, Opheim LO, et al
Physical activity and lower extremity lymphedema among endometrial cancer survivors: A population-based cross-sectional study.
Gynecol Oncol. 2025;195:82-88.
PubMed Abstract available

LINDEMANN K, Siegenthaler F, Lande KT, Casas-Arozamena C, et al
Prognostic value of assessing ctDNA in patients with endometrial carcinoma - an international multicenter study.
Gynecol Oncol. 2025;195:98-105.
PubMed Abstract available

ZAMMARRELLI WA 3RD, Nandakumar S, Kertowidjojo E, Nguyen B, et al
The genomic landscape of distant metastatic endometrial cancer.
Gynecol Oncol. 2025;195:89-97.
PubMed Abstract available

TYAN K, Liu KX, Smart AC, Feltmate CM, et al
Role of adjuvant radiotherapy modality on clinical outcomes for early-stage uterine carcinosarcoma.
Gynecol Oncol. 2025;195:75-81.
PubMed Abstract available

CARTER J, Huang HQ, Monk BJ, Kim YB, et al
Evaluation of physical function and quality of life before and after nonradical surgical therapy for stage IA1 and IA2-IB1 cervical cancer (GOG-0278).
Gynecol Oncol. 2025;195:50-58.
PubMed Abstract available

BAE-JUMP VL, Sill MW, Gehrig PA, Merker JD, et al
A randomized phase II/III study of paclitaxel/carboplatin/metformin versus paclitaxel/carboplatin/placebo as initial therapy for measurable stage III or IVA, stage IVB, or recurrent endometrial cancer: An NRG oncology/GOG study.
Gynecol Oncol. 2025;195:66-74.
PubMed Abstract available

COVENS A, Huang HQ, Monk BJ, Kim YB, et al
Evaluation of efficacy and fertility after nonradical surgical therapy (extra fascial hysterectomy or cone biopsy, with pelvic lymphadenectomy) for stage IA1, IA2, and IB1 cervical cancer (GOG-0278).
Gynecol Oncol. 2025;195:59-65.
PubMed Abstract available

LA TORRE F, Hurni Y, Farsi E, Nardi E, et al
Adenomyosis associated with endometrial cancer: Possible correlation with pathological, immunohistochemical and molecular characteristics.
Gynecol Oncol. 2025;195:45-49.
PubMed Abstract available

LI X, Wang Z, Man X, Dai X, et al
Research advances CRISPR gene editing technology generated models in the study of epithelial ovarian carcinoma.
Gynecol Oncol. 2025;195:34-44.
PubMed Abstract available

HICKS A, Borho L, Elishaev E, Berger J, et al
All-cause mortality and neighborhood social vulnerability among women with ovarian cancer.
Gynecol Oncol. 2025;195:26-33.
PubMed Abstract available

MARCHETTI C, Ergasti R, Capomacchia FM, Giannarelli D, et al
Integrating clinical-molecular data to predict PARP inhibitors efficacy in advanced ovarian cancer patients after interval cytoreductive surgery.
Gynecol Oncol. 2025;195:16-25.
PubMed Abstract available

FUCA G, Dell'Acqua C, Peruffo B, Lalli G, et al
WRN dependency in dMMR/MSI-H endometrial cancer: Clinical perspectives of a novel synthetic lethality strategy.
Gynecol Oncol. 2025;195:12-15.
PubMed

DINKINS KG, Lee GM, Arend RC, Leath CA 3rd, et al
Trends in FDA approvals of gynecologic oncology therapeutics from 2019 to 2024.
Gynecol Oncol. 2025;194:153-158.
PubMed Abstract available

HERZOG TJ, Liao JB, Finkelstein K, Willmott L, et al
An open-label randomized active-controlled phase II clinical study to assess the efficacy and safety of afuresertib plus paclitaxel versus paclitaxel in patients with platinum-resistant ovarian cancer (PROFECTA-II/GOG-3044).
Gynecol Oncol. 2025;194:145-152.
PubMed Abstract available

WENZEL L, McKinney C, Jensen S, Peipert D, et al
Ensuring relevance and equity in patient reported outcomes (PROs) in endometrial cancer: The SGO promote study (Patient Reported Outcomes Measurement Opportunities Through Equity).
Gynecol Oncol. 2025;194:137-144.
PubMed Abstract available

VELASQUEZ J, Mohammed-Norgan M, Scheiber A, Chalif J, et al
Cross-language insights: Comparing Spanish and English-language cervical cancer content on TikTok.
Gynecol Oncol. 2025;194:131-136.
PubMed Abstract available

LI J, Welte T, Calzoncinth K, Vuttaradhi VK, et al
An inducible FOXL2-dependent mouse model of ovarian adult type granulosa cell tumor.
Gynecol Oncol. 2025;194:125-130.
PubMed Abstract available

DEBBICHE I, Wang CC, Gomez-Roas M, Foley OW, et al
Rest assured: High sleep efficiency reduces postoperative complications and opioid prescriptions in patients undergoing surgeries with gynecologic oncologists.
Gynecol Oncol. 2025;194:119-124.
PubMed Abstract available

VAN VELZEN AF, Tulling AJ, van Poelgeest MIE, Bosse T, et al
Predicting lymph node metastases in three different vulvar squamous cell carcinoma subgroups.
Gynecol Oncol. 2025;194:86-90.
PubMed Abstract available

ZANNONI GF, Angelico G, Spadola S, Bragantini E, et al
Chemotherapy Response Score (CRS): A comprehensive review of its prognostic and predictive value in High-Grade Serous Carcinoma (HGSC).
Gynecol Oncol. 2025;194:1-10.
PubMed Abstract available

ESKANDER RN
Implications of the platinum-free interval in endometrial cancer: A legacy worth leaving behind?
Gynecol Oncol. 2025;194:A3-A4.
PubMed

February 2025

WALKER AR, Leite S, Chen YS, Huepenbecker SP, et al
Sentinel lymph node biopsy at the time of hysterectomy for early-stage cervical cancer: A cost-effectiveness analysis.
Gynecol Oncol. 2025;195:1-5.
PubMed Abstract available

ASARE A, Previs RA, Spinosa D, Fellman B, et al
Bevacizumab beyond progression: Impact of subsequent bevacizumab re-treatment in patients with ovarian, fallopian tube, and peritoneal cancer after progression.
Gynecol Oncol. 2025;194:112-118.
PubMed Abstract available

HAIGHT PJ, Sanchez M, Thomas SM, Smitherman C, et al
Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer: A real-world endometrial cancer molecularly targeted therapy consortium cohort study.
Gynecol Oncol. 2025;194:98-104.
PubMed Abstract available

NOLIN AC, Atkins SL, Myers ER, Wentzensen N, et al
Ultrasound-based versus immediate biopsy-based management of postmenopausal bleeding in non-Hispanic Black and non-Hispanic White individuals.
Gynecol Oncol. 2025;194:105-111.
PubMed Abstract available

MACDUFFIE E, Kernell C, George J, Bvochora-Nsingo M, et al
Efficacy of induction chemotherapy during the COVID-19 pandemic for treatment of locally advanced cervical cancer in Botswana.
Gynecol Oncol. 2025;194:91-97.
PubMed Abstract available

HAIGHT P, Bilbe C, Riedinger C, Backes F, et al
Defining "enlarged" sentinel lymph nodes in the setting of endometrial cancer: What is the size cut-off?
Gynecol Oncol. 2025;194:80-85.
PubMed Abstract available

ALVERO AB, Wu S, Farrell A, Kim S, et al
Exploring the differences between BRCA mutated and HRwild-type high grade serous ovarian cancer: A multiomic analysis.
Gynecol Oncol. 2025;194:71-79.
PubMed Abstract available

SUN H, Huo X, Bi X, Cao D, et al
Exosome transmit the ability of migration and invasion in heterogeneous ovarian cancer cells by regulating autophagy via targeting hsa-miR-328.
Gynecol Oncol. 2025;194:60-70.
PubMed Abstract available

MATSUO K, Agarwal J, Chen L, Furey KB, et al
Histology-specific prognostic significance of isolated tumor cells, micrometastases, and macrometastases in endometrial cancer.
Gynecol Oncol. 2025;194:51-59.
PubMed Abstract available

TUBRIDY EA, Campbell A, Mulugeta-Gordon L, Andriani L, et al
Impact of telehealth legislation on gynecologic oncology services: Policy updates.
Gynecol Oncol. 2025;194:48-50.
PubMed

GAILLARD S, Verma N, Berg M, Harrison J, et al
A clinical study of tremelimumab, alone or in combination with olaparib, for recurrent epithelial ovarian cancer.
Gynecol Oncol. 2025;194:41-47.
PubMed Abstract available

CORTES-SALGADO A, Moreno-Moreno E, Carretero-Barrio I, Caniego-Casas T, et al
HER2 expression in a molecularly defined cohort of endometrial cancer patients: The SPECTRUM study.
Gynecol Oncol. 2025;194:33-40.
PubMed Abstract available

KIM J, Park SY, Kim JH, Lee SW, et al
Real-world efficacy and toxicity of olaparib maintenance therapy in Korean ovarian cancer patients with an exploratory analysis of BRCA mutations.
Gynecol Oncol. 2025;194:25-32.
PubMed Abstract available

ROMERO IL, Lengyel E, Wahner Hendrickson AE, Rodriguez GC, et al
Metformin for patients with advanced stage ovarian cancer: A randomized phase II placebo-controlled trial.
Gynecol Oncol. 2025;194:18-24.
PubMed Abstract available

VALENZA C, Mongillo M, Visconti MV, Katrini J, et al
Rechallenge with platinum-based chemotherapy in patients with platinum-resistant ovarian carcinoma: A cohort study.
Gynecol Oncol. 2025;194:11-17.
PubMed Abstract available

CORVIGNO S, Fernebro J, Karlsson JS, Mezheieusky A, et al
High prevalence of FAP+ cancer-associated fibroblasts predicts poor outcome in patients with high-grade serous ovarian cancer with high CD8 T-cell density.
Gynecol Oncol. 2025;193:148-155.
PubMed Abstract available

STUEBS FA, Knoll A, Hartmann A, Leikauf LS, et al
PD-L1-Expression in primary and recurrent vulvar squamous cell cancer.
Gynecol Oncol. 2025;193:98-104.
PubMed Abstract available

HOROWITZ NS, St Laurent JD, Berkowitz RS
Prevention of gestational trophoblastic neoplasia with actinomycin -D at the time of evacuation: A matter of routine practice or reserve for special circumstances?
Gynecol Oncol. 2025;193:A1-A2.
PubMed

January 2025

MAKI PM, Rubin LH, Krejany EO, Brand A, et al
What happens after menopause? (WHAM): A prospective controlled study of cognition 24 months after premenopausal risk-reducing salpingo-oophorectomy.
Gynecol Oncol. 2025;193:141-147.
PubMed Abstract available

KIM YJ, Lee J, Park S, Kim YM, et al
The value of magnetic resonance imaging in predicting vesicovaginal fistula in cervical cancer with bladder invasion treated with definitive chemoradiotherapy.
Gynecol Oncol. 2025;193:136-140.
PubMed Abstract available

CLEMENTS A, Enserro D, Strickland KC, Previs R, et al
Molecular classification of endometrial cancers (EC) and association with relapse-free survival (RFS) and overall survival (OS) outcomes: Ancillary analysis of GOG-0258.
Gynecol Oncol. 2025;193:119-129.
PubMed Abstract available

O'MALLEY DM, Bariani GM, Cassier PA, Marabelle A, et al
Pembrolizumab in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) and non-MSI-H/non-dMMR advanced endometrial cancer: Phase 2 KEYNOTE-158 study results.
Gynecol Oncol. 2025;193:130-135.
PubMed Abstract available

TOBONI MD, Dinkins K, Wu S, Mattox T, et al
Not all uterine carcinosarcomas are created equal: Survival outcomes according to molecular characterization of uterine carcinosarcoma.
Gynecol Oncol. 2025;193:89-97.
PubMed Abstract available

SCHAAFSMA M, Schuurman TN, Siebers AG, Bekkers RLM, et al
Cost-effectiveness of an additional hysterectomy after initially conservative treatment for cervical adenocarcinoma in situ.
Gynecol Oncol. 2025;193:113-118.
PubMed Abstract available

UBERTI EMH, de Freitas Medeiros LR, Cardoso RB, Muller KP, et al
Primary prevention of post-molar gestational trophoblastic neoplasia in high-risk complete hydatidiform mole: A single-dose prophylactic actinomycin D, associated with uterine evacuation - a long retrospective cohort study.
Gynecol Oncol. 2025;193:105-112.
PubMed Abstract available

DE VITIS LA, Reyes-Baez FE, Schivardi G, Shahi M, et al
Cervical stromal invasion and molecular characterization in stage II-IV endometrial cancers.
Gynecol Oncol. 2025;193:81-88.
PubMed Abstract available

WANG H, Zhu J, Zou D, Rao Q, et al
Multicenter study of ovarian cancer score for diagnosing ovarian cancer.
Gynecol Oncol. 2025;193:58-64.
PubMed Abstract available

AHMED J, Stephen B, Khawaja MR, Yang Y, et al
A phase I study of temsirolimus in combination with metformin in patients with advanced or recurrent endometrial cancer.
Gynecol Oncol. 2025;193:73-80.
PubMed Abstract available

MIRZA HB, Hunt A, Ennis DP, McDermott J, et al
Spatial transcriptomic analysis reveals significant differences in tumor microenvironment in HPV-dependent and HPV-independent vulvar squamous cell carcinoma.
Gynecol Oncol. 2025;193:65-72.
PubMed Abstract available

LEIJTENS L, Piek J, Verrijssen AS, Rijkaart D, et al
Thromboprophylaxis in patients with locally advanced cervical cancer treated with chemoradiation and brachytherapy.
Gynecol Oncol. 2025;193:41-48.
PubMed Abstract available

RICCIUTI J, Liu Q, Khan ANMNH, Joseph JM, et al
Prognostic significance of serum complement activation, neutrophil extracellular traps and extracellular DNA in newly diagnosed epithelial ovarian cancer.
Gynecol Oncol. 2025;193:49-57.
PubMed Abstract available

BOGANI G, Moore KN, Ray-Coquard I, Lorusso D, et al
Incorporating immune checkpoint inhibitors in epithelial ovarian cancer.
Gynecol Oncol. 2025;193:30-40.
PubMed Abstract available

WALKER AR, Leite S, Taylor N, Graul A, et al
Lymph node assessment at the time of robotic hysterectomy for endometrial intraepithelial neoplasia: A cost-effectiveness analysis.
Gynecol Oncol. 2025;193:24-29.
PubMed Abstract available

SIEGENTHALER F, Imboden S, Buchi C, Christe L, et al
Added prognostic value of sentinel lymph node mapping in endometrial cancer to molecular subgroups.
Gynecol Oncol. 2025;193:12-19.
PubMed Abstract available

VOSS FO, Fons G, Bruggink AH, Wenzel HHB, et al
Prevalence and impact of vulvar lesions diagnosed prior to vulvar squamous cell carcinoma: A population-based cohort study.
Gynecol Oncol. 2025;192:163-170.
PubMed Abstract available

MARINO G, Marchetta L, Negri S, Testa F, et al
Oncologic and fertility outcomes in patients with juvenile granulosa cell tumor - a retrospective single centre analysis.
Gynecol Oncol. 2025;192:89-93.
PubMed Abstract available

December 2024

NEILSON A, Jamieson A, Chiu D, Leung S, et al
Serum CA125 levels in the context of ProMisE molecular classification provides pre-operative prognostic information that can direct endometrial cancer management.
Gynecol Oncol. 2024;193:1-11.
PubMed Abstract available

MADDY BP, Tischer KM, McGree ME, Fought AJ, et al
Implementation of enhanced recovery protocol did not increase rates of acute kidney injury in open gynecologic oncology surgery: A single-institution experience.
Gynecol Oncol. 2024;192:181-188.
PubMed Abstract available

VOS JAM, Vos MC, van Lonkhuijzen LRCW, van de Poll-Franse LV, et al
Less is more: The benefits of reduced follow-up in gynecologic cancers.
Gynecol Oncol. 2024;192:178-180.
PubMed

LIU YL, Praiss AM, Chiang S, Devereaux K, et al
Gestational trophoblastic neoplasm: Patient outcomes and clinical pearls from a multidisciplinary referral center.
Gynecol Oncol. 2024;192:171-177.
PubMed Abstract available

KONUMA M, Ikeda T, Mitoma T, Shirakawa S, et al
Effectiveness of exercise therapy on chemotherapy-induced peripheral neuropathy in patients with ovarian cancer: A scoping review.
Gynecol Oncol. 2024;192:155-162.
PubMed Abstract available

AZAIS H, Brochard C, Taly V, Benoit L, et al
Prognostic value of circulating tumor DNA at diagnosis and its early decrease after one cycle of neoadjuvant chemotherapy for patients with advanced epithelial ovarian cancer. An ancillary analysis of the CHIVA phase II GINECO trial.
Gynecol Oncol. 2024;192:145-154.
PubMed Abstract available

NGUYEN T, Yi Y, Morron S, Brittain D, et al
Living in a food desert in Louisiana and its effects on gynecologic cancer outcomes.
Gynecol Oncol. 2024;192:137-144.
PubMed Abstract available

MIRZA MR, Bjorge L, Marme F, Christensen RD, et al
Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trial.
Gynecol Oncol. 2024;192:128-136.
PubMed Abstract available

GRAVES S, Sullivan MW, Adkoli A, Zhou Q, et al
Association between genomic instability score and progression-free/overall survival in patients with newly diagnosed non-BRCA1/2 ovarian cancer.
Gynecol Oncol. 2024;192:120-127.
PubMed Abstract available

CASTELLANO T, Lara OD, McCormick C, Chase D, et al
Clinical trial screening in gynecologic oncology: Defining the need and identifying best practices.
Gynecol Oncol. 2024;192:111-119.
PubMed Abstract available

PREVIS RA, Strickland KC, Wallen Z, Ko H, et al
Analysis of real world FRalpha testing in ovarian, fallopian tube, and primary peritoneal cancers.
Gynecol Oncol. 2024;192:102-110.
PubMed Abstract available

COLSON-FEARON D, Viswanathan AN
Trends in brachytherapy in utilization for vaginal cancer in the United States from 2004 to 2021.
Gynecol Oncol. 2024;191:228-232.
PubMed Abstract available

MOUFARRIJ S, Dagher C, Filippova OT, Zhou Q, et al
Five-year quality-of-life assessment by urinary diversion type after pelvic Exenterations.
Gynecol Oncol. 2024;191:212-218.
PubMed Abstract available

FEDERICO A, Lancellotta V, Fragomeni SM, Macchia G, et al
Surgery after upfront chemoradiation in locally advanced squamous cell vulvar cancer: Analysis of postoperative outcomes and survival.
Gynecol Oncol. 2024;191:106-113.
PubMed Abstract available

WONG TY, Adzibolosu NK, Mattei LH, Speak AC, et al
Disparities in contemporary human papilloma virus vaccination uptake among adult women living in the United States: An All of Us Research Program study.
Gynecol Oncol. 2024;191:100-105.
PubMed Abstract available

THAYER EG, Manning-Geist BL
Following the folate receptor: Expanding targeted treatment options in low grade serous ovarian carcinoma.
Gynecol Oncol. 2024;191:A1-A2.
PubMed

November 2024

SHU T, Liang Y, Zhang S, Sun T, et al
The prognostic value of tumor-informed minimal residual disease detection using circulating tumor DNA in first-line treatment of ovarian cancer.
Gynecol Oncol. 2024;192:94-101.
PubMed Abstract available

BORHO L, Elishaev E, Bao R, O'Brien E, et al
Association of neighborhood social vulnerability with ovarian cancer survival.
Gynecol Oncol. 2024;192:32-39.
PubMed Abstract available

KLEPPE A, Lindemann K, Kildal W, Tobin KAR, et al
Prognostic and therapeutic implication of molecular classification including L1CAM expression in high-risk endometrial cancer.
Gynecol Oncol. 2024;192:80-88.
PubMed Abstract available

CLASSEN CC, Chivers ML, Brotto LA, Barbera L, et al
A randomized controlled trial of an online support group addressing psychosexual distress among women treated for gynecologic cancer.
Gynecol Oncol. 2024;192:73-79.
PubMed Abstract available

SONAVANE M, Hedlich-Dwyer J, Dal Zotto VL, Tang M, et al
Repair Assisted Damage Detection (RADD) as a predictive biomarker for immunotherapy response in ovarian cancer.
Gynecol Oncol. 2024;192:65-72.
PubMed Abstract available

KHADRAOUI W, Sinnott JA, Meade CE, Plascak J, et al
Clinical trial enrollment during first course of gynecologic cancer treatment and survival.
Gynecol Oncol. 2024;192:59-64.
PubMed Abstract available

MULUGETA-GORDON L, Smith AJB
Insurance coverage and access to gynecologic oncology: Where are we are now.
Gynecol Oncol. 2024;192:56-58.
PubMed Abstract available

FRANCIS KE, Simon S, Gebski V, Joly F, et al
Adverse events in the placebo arm of SOLO2/ENGOT-Ov21 maintenance trial of olaparib in recurrent ovarian cancer.
Gynecol Oncol. 2024;192:50-55.
PubMed Abstract available

POWELL MA, Cibula D, O'Malley DM, Boere I, et al
Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).
Gynecol Oncol. 2024;192:40-49.
PubMed Abstract available

COLEMAN RL, Lubinga SJ, Shen Q, Walder L, et al
Cost-effectiveness of dostarlimab plus carboplatin-paclitaxel for primary advanced or recurrent endometrial cancer from a US payer perspective.
Gynecol Oncol. 2024;192:24-31.
PubMed Abstract available

DE JAEGHERE EA, Hamerlinck H, Tuyaerts S, Lippens L, et al
Associations of the gut microbiome with outcomes in cervical and endometrial cancer patients treated with pembrolizumab: Insights from the phase II PRIMMO trial.
Gynecol Oncol. 2024;191:275-286.
PubMed Abstract available

VREDE SW, Van Weelden WJ, Bulten J, Gilks CB, et al
Hormonal biomarkers remain prognostically relevant within the molecular subgroups in endometrial cancer.
Gynecol Oncol. 2024;192:15-23.
PubMed Abstract available

MOUFARRIJ S, Lakhman Y, Aghajanian C, Abu-Rustum NR, et al
Evolutionary pathways in early-stage, non-myoinvasive endometrioid endometrial cancers of no specific molecular profile.
Gynecol Oncol. 2024;192:8-14.
PubMed Abstract available

HICKEY M, Nguyen TL, Krejany EO, Domchek SM, et al
What happens after menopause? (WHAM): Impact of risk-reducing salpingo-oophorectomy on depressive and anxiety symptoms at 24 months.
Gynecol Oncol. 2024;192:1-7.
PubMed Abstract available

KILOWSKI KA, Dietrich MF, Xiu J, Baca Y, et al
KRAS mutations in endometrial cancers: Possible prognostic and treatment implications.
Gynecol Oncol. 2024;191:299-306.
PubMed Abstract available

LEE AW, Poynor V, Siddiqui S
Disparities in ovarian cancer survival among ethnic Asian American populations, 2006-2020.
Gynecol Oncol. 2024;191:292-298.
PubMed Abstract available

BOITANO TKL, Blank SV, Havrilesky LJ, Huh WK, et al
Too much of a good thing? Projecting the need for gynecologic oncologists over the next 20 years.
Gynecol Oncol. 2024;191:287-291.
PubMed Abstract available

JAIN D, Zaeim F, Wahidi M, Smith WJ, et al
Cervical squamous cell carcinoma outcomes across continents: A retrospective study.
Gynecol Oncol. 2024;190:272-282.
PubMed Abstract available

PROPPE L, Jaeger A, Goy Y, Petersen C, et al
Systematic review - Adjuvant radiotherapy of the vulva in primary vulvar cancer.
Gynecol Oncol. 2024;190:264-271.
PubMed Abstract available

CHOI YK, Lee JH, Kim YS, Wee CW, et al
Mid-treatment MRI-based tumor response assessment for tumor recurrence and patient survival in locally advanced adenocarcinoma of the cervix: A retrospective multicenter study of KROG 23-03.
Gynecol Oncol. 2024;190:222-229.
PubMed Abstract available

SHIBATA M, Yoshida K, Yokoi A, Suzuki H, et al
Elucidation of the role of XBP1 in the progression of complete hydatidiform mole to invasive mole through RNA-seq.
Gynecol Oncol. 2024;190:189-199.
PubMed Abstract available

NONZEE NJ, Thiel de Bocanegra H, Navarro S, Bastani R, et al
Impact of management guidelines for abnormal cervical cytology on colposcopy procedure rates among young women.
Gynecol Oncol. 2024;190:160-166.
PubMed Abstract available

HEUS C, Stelten S, Kenter GG, Buffart LM, et al
Body composition and peri- and postoperative complications in patients with gynaecological malignancies: A systematic review.
Gynecol Oncol. 2024;190:131-138.
PubMed Abstract available

WEBBER JW, Wollborn L, Mishra S, Vitonis AF, et al
Serum miRNA improves the accuracy of a multivariate index assay for triage of an adnexal mass.
Gynecol Oncol. 2024;190:124-130.
PubMed Abstract available

METCALF CA, Page CE, Stocker BOS, Johnson RL, et al
Treating new-onset cognitive complaints after risk-reducing salpingo-oophorectomy: A randomized controlled crossover trial of lisdexamfetamine.
Gynecol Oncol. 2024;190:62-69.
PubMed Abstract available

MERTEN R, Strnad V, Karius A, Lotter M, et al
Brachytherapy in vaginal cancer for organ preservation: Clinical outcome and safety from a single center experience.
Gynecol Oncol. 2024;190:35-41.
PubMed Abstract available

TEE XR, Hazard E, Latorre-Esteves E, Kohrn BF, et al
Increased TP53 somatic evolution in peritoneal washes of individuals with BRCA1 germline mutations.
Gynecol Oncol. 2024;190:18-27.
PubMed Abstract available

BROWN J
Hormonal maintenance therapy for advance low grade serous ovarian carcinoma appears to be of benefit - That's a relief!
Gynecol Oncol. 2024;190:A1-A2.
PubMed

October 2024

VER HOEVE ES, Rumble ME, Gorzelitz JS, Rose SL, et al
Biobehavioral predictors of mood, pain, fatigue, and insomnia in endometrial cancer survivors.
Gynecol Oncol. 2024;191:265-274.
PubMed Abstract available

HUNSBERGER KS, Tewari KS, Monk BJ, Chase DM, et al
Standard of care treatment for stage IVB cervical cancer: A systematic review and meta-analysis.
Gynecol Oncol. 2024;191:259-264.
PubMed Abstract available

MOORE KN, Lorusso D, Oaknin A, Oza A, et al
Safety and tolerability of mirvetuximab soravtansine monotherapy for folate receptor alpha-expressing recurrent ovarian cancer: An integrated safety summary.
Gynecol Oncol. 2024;191:249-258.
PubMed Abstract available

PENG S, Zheng Y, Liu J, Chen S, et al
Molecular classification in fertility-sparing treatment of early-stage endometrial cancer: A potential tool for optimizing patient selection.
Gynecol Oncol. 2024;191:240-248.
PubMed Abstract available

GARCIA-DONAS J, Redondo A, Santaballa A, Garrigos L, et al
Phase II clinical trial assessing the efficacy of enzalutamide in advanced non-resectable granulosa cell ovarian tumors: The GREKO III study (GETHI2016-01).
Gynecol Oncol. 2024;191:233-239.
PubMed Abstract available

NAGASE Y, Matsuo K, Nakao Y, Hisa T, et al
Adjuvant therapy de-escalation for stage I uterine leiomyosarcoma: A systematic review and meta-analysis.
Gynecol Oncol. 2024;191:219-227.
PubMed Abstract available

LI G, Li X, Yin R, Feng M, et al
Phase II study of enlonstobart (SG001), a novel PD-1 inhibitor in patients with PD-L1 positive recurrent/metastatic cervical cancer.
Gynecol Oncol. 2024;191:165-171.
PubMed Abstract available

HICKEY M, Trainer AH, Krejany EO, Brand A, et al
What happens after menopause? (WHAM): A prospective controlled study of vasomotor symptoms and menopause-related quality of life 24 months after premenopausal risk-reducing salpingo-oophorectomy (RRSO).
Gynecol Oncol. 2024;191:201-211.
PubMed Abstract available

HAIGHT PJ, Lammers S, Kistenfeger Q, Leipold C, et al
Cold ischemia time and formalin fixation time in endometrial cancer: Should breast cancer guidelines for preanalytical variables be applied to hysterectomy specimens?
Gynecol Oncol. 2024;191:194-200.
PubMed Abstract available

YONEMORI K, Boni V, Min KG, Meniawy TM, et al
Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and combined with abemaciclib, in recurrent/advanced ER-positive endometrioid endometrial cancer: Results from the phase 1a/1b EMBER study.
Gynecol Oncol. 2024;191:172-181.
PubMed Abstract available

ELAYAPILLAI SP, Dogra S, Lausen J, Parker M, et al
ATR inhibition increases reliance on PARP-mediated DNA repair revealing an improved therapeutic strategy for cervical cancer.
Gynecol Oncol. 2024;191:182-193.
PubMed Abstract available

PLINSINGA ML, Rye S, Jones T, Vagenas D, et al
Mild symptoms matter: Results from a prospective, longitudinal study on the relationship between symptoms, lymphedema and health-related outcomes post-gynecological cancer.
Gynecol Oncol. 2024;191:158-164.
PubMed Abstract available

PERRONE E, Capasso I, Giannarelli D, Trozzi R, et al
Less is more? Comparison between genomic profiling and immunohistochemistry-based models in endometrial cancer molecular classification: A multicenter, retrospective, propensity-matched survival analysis.
Gynecol Oncol. 2024;191:150-157.
PubMed Abstract available

OGASAWARA A, Matsushita H, Tan TZ, Shintani D, et al
Immunological impact of intraperitoneal and intravenous chemotherapy in ovarian cancer, translational analyses of the Phase 3 iPocc trial.
Gynecol Oncol. 2024;191:124-131.
PubMed Abstract available

SAAB R, Fellman BM, Legarreta AF, Meyer LA, et al
Comparative analysis of hormonal therapy in low-grade endometrial stromal sarcoma: A retrospective study.
Gynecol Oncol. 2024;191:143-149.
PubMed Abstract available

PINTO P, Moro F, Alcazar JL, Alessi S, et al
Prediction of non-resectability in tubo-ovarian cancer patients using Peritoneal Cancer Index - A prospective multicentric study using imaging (ISAAC study).
Gynecol Oncol. 2024;191:132-142.
PubMed Abstract available

KONG W, Deng B, Shen X, John C, et al
Tirzepatide as an innovative treatment strategy in a pre-clinical model of obesity-driven endometrial cancer.
Gynecol Oncol. 2024;191:116-123.
PubMed Abstract available

NG ZY, Manchanda R, Lopez A, Obermair A, et al
The prognosis of stage IA cervical cancer: Subgroup analysis of the SCCAN study.
Gynecol Oncol. 2024;191:95-99.
PubMed Abstract available

CARUSO G, Langstraat CL, Kumar A, McGree ME, et al
Textbook oncologic outcome is an easy-to-use composite quality measure that is strongly associated with survival in advanced-stage ovarian cancer.
Gynecol Oncol. 2024;191:86-94.
PubMed Abstract available

RUSHTON T, Krause HB, Samec T, Elliott A, et al
Characterizing the genomic landscape through the lens of FOLR1 status in low and high grade serous ovarian carcinoma.
Gynecol Oncol. 2024;191:80-85.
PubMed Abstract available

LIAO JB, Jejurikar NS, Hitchcock-Bernhardt KM, Gwin WR, et al
Intraperitoneal immunotherapy with denileukin diftitox (ONTAK) in recurrent refractory ovarian cancer.
Gynecol Oncol. 2024;191:74-79.
PubMed Abstract available

BRITTON MC, Izampuye E, Clark M, Ornstein RA, et al
Diagnostic experiences of Black and White patients with uterine cancer: A qualitative study.
Gynecol Oncol. 2024;191:67-73.
PubMed Abstract available

VAZ J, Piver R, Brzezinska B, Suhner J, et al
Nutrition's checkpoint inhibition: The impact of nutrition on immunotherapy outcomes.
Gynecol Oncol. 2024;189:129-136.
PubMed Abstract available

September 2024

WAN S, Gao Y, Wu S, Wang H, et al
Somatic mutation of targeted sequencing identifies risk stratification in advanced ovarian clear cell carcinoma.
Gynecol Oncol. 2024;191:56-66.
PubMed Abstract available

LINDQUIST S, Kjaer SK, Frederiksen K, Ornskov D, et al
Comparative analysis of HPV testing versus cytology in Danish cervical cancer screening: Insights from a large-scale implementation study.
Gynecol Oncol. 2024;191:45-55.
PubMed Abstract available

PRAISS AM, Dagher C, Zhou Q, Iasonos A, et al
Lymph node metastases in endometrial carcinoma: A modern assessment in the era of sentinel lymph node mapping and molecular subtyping.
Gynecol Oncol. 2024;191:37-44.
PubMed Abstract available

YANG X, Li C, Li Z, Du D, et al
The clinical value of ultrasound-guided sacral anesthesia in Intracavitary and/or interstitial brachytherapy for cervical Cancer.
Gynecol Oncol. 2024;191:31-36.
PubMed Abstract available

LI X, Argenta PA, Brown K, Honeyfield K, et al
Associations of cytomegalovirus infection with cancer-related cognitive impairment and peripheral neuropathy in ovarian cancer survivors.
Gynecol Oncol. 2024;191:25-30.
PubMed Abstract available

JANG EB, Lee AJ, So KA, Lee SJ, et al
Risk factors for the recurrence in patients with early endometrioid endometrial cancer achieving complete remission for fertility-sparing hormonal treatment.
Gynecol Oncol. 2024;191:19-24.
PubMed Abstract available

ANASTASIO MK, Nolin A, Penvose KN, Lambert K, et al
Adjuvant therapy and recurrence risk in non-myoinvasive high-grade (stage IC) endometrial cancer: A systematic review and meta-analysis.
Gynecol Oncol. 2024;191:10-18.
PubMed Abstract available

NIEF CA, Long SE, McCleary TL, Kidd E, et al
Diabetes mellitus complications associated with recurrence of stage I endometrioid endometrial cancer: A single-center retrospective study.
Gynecol Oncol. 2024;190:298-306.
PubMed Abstract available

MOUFARRIJ S, Gazzo A, Rana S, Selenica P, et al
Concurrent POLE hotspot mutations and mismatch repair deficiency/microsatellite instability in endometrial cancer: A challenge in molecular classification.
Gynecol Oncol. 2024;191:1-9.
PubMed Abstract available

FULLERTON R, Martell K, Khanolkar R, Phan T, et al
Impact of immune, inflammatory and nutritional indices on outcome in patients with locally advanced cervical cancer treated with definitive (chemo)radiotherapy.
Gynecol Oncol. 2024;190:291-297.
PubMed Abstract available

BROWN J, Miller A, Holman LL, Backes F, et al
Results of a randomized phase II trial of paclitaxel and carboplatin versus bleomycin, etoposide and cisplatin for newly diagnosed and recurrent Chemonaive stromal ovarian tumors: An NRG oncology/gynecologic oncology group study14.
Gynecol Oncol. 2024;190:283-290.
PubMed Abstract available

NAHSHON C, Leitao MM Jr, Segev Y
Response to the letter to the editor: Referring to the manuscript entitled "Surgical nodal assessment for endometrial hyperplasia - A meta-analysis and systematic review".
Gynecol Oncol. 2024;190:262-263.
PubMed

ADJEI NN, Haas A, Zhao H, Primm KM, et al
Real-world trends in the use of maintenance therapy in ovarian cancer across the United States from 2017 to 2021.
Gynecol Oncol. 2024;190:255-261.
PubMed Abstract available

NGUYEN L, Chung TH, Le YL, Reygaerts H, et al
Hispanic individuals' cervical cancer screening disparities amidst the COVID-19 pandemic.
Gynecol Oncol. 2024;190:243-249.
PubMed Abstract available

RIOS-DORIA E, Nobre SP, Sassine D, Glaser G, et al
Impact of adjuvant therapy on oncologic outcomes in uterine-confined clear cell carcinoma of the endometrium.
Gynecol Oncol. 2024;190:236-242.
PubMed Abstract available

MOKSHAGUNDAM S, McGree ME, Tapia AL, Fought AJ, et al
Physical and psychological distress amongst patients undergoing neoadjuvant chemotherapy for advanced ovarian cancer.
Gynecol Oncol. 2024;190:230-235.
PubMed Abstract available

YOUNG AN, Lin LH, Abel MK, Badhey MO, et al
Atypical placental site nodules: Clinicopathologic features, management and patient outcomes in an institutional series.
Gynecol Oncol. 2024;190:215-221.
PubMed Abstract available

POTHURI B, Sawaged Z, Karpel HC, Li X, et al
A phase 2 feasibility study of nab-paclitaxel and carboplatin in epithelial carcinoma of the uterus.
Gynecol Oncol. 2024;190:209-214.
PubMed Abstract available

PIFER PM, Kilar CR, Beriwal S
Is substantial lymphovascular space invasion in FIGO stage I endometrial carcinoma ready for primetime in deciding adjuvant treatment?
Gynecol Oncol. 2024;188:A1-A3.
PubMed

WALL JA, Pozzar RA, Enzinger AC, Tavormina A, et al
Improving the palliative-procedure decision-making process for patients with peritoneal carcinomatosis: A secondary analysis.
Gynecol Oncol. 2024;188:125-130.
PubMed Abstract available

WILKE RN, Iniesta MD, Fellman B, Jazaeri AA, et al
A colostomy for large bowel obstruction at the end of life: What do patients gain from palliative surgery?
Gynecol Oncol. 2024;188:120-124.
PubMed Abstract available

MONK BJ, Tewari KS, Randall LM, Pothuri B, et al
Immunotherapy in locally advanced cervix cancer: A critical appraisal of the FDA indication based on ENGOT-CX11/GOG-3047/KEYNOTE-A18.
Gynecol Oncol. 2024;188:81-82.
PubMed

LAMBERT KA, Albright BB, Anastasio MK, Kaplan SJ, et al
Scalp hypothermia to reduce chemotherapy-induced alopecia: A systematic review and meta-analysis.
Gynecol Oncol. 2024;188:71-80.
PubMed Abstract available

WILHITE AM, Wu S, Xiu J, Gibney GT, et al
A paradigm shift in understanding vulvovaginal melanoma as a distinct tumor type compared with cutaneous melanoma.
Gynecol Oncol. 2024;188:13-21.
PubMed Abstract available

POZZAR RA, Enzinger AC, Howard C, Tavormina A, et al
Feasibility and acceptability of a nurse-led telehealth intervention (BOLSTER) to support patients with peritoneal carcinomatosis and their caregivers: A pilot randomized clinical trial.
Gynecol Oncol. 2024;188:1-7.
PubMed Abstract available

August 2024

LIM H, Kim SI, Kim MK, Yoon SH, et al
Initial sarcopenia and body composition changes as prognostic factors in cervical cancer patients treated with concurrent chemoradiation: An artificial intelligence-based volumetric study.
Gynecol Oncol. 2024;190:200-208.
PubMed Abstract available

MILLER EA, Chowdhary B, Chapman-Davis E
Beyond the decision: Reproductive justice and cervical cancer care in a post-Dobbs era.
Gynecol Oncol. 2024;190:186-188.
PubMed Abstract available

MEERNIK C, Osazuwa-Peters OL, Wilson LE, Joshi A, et al
Frailty in patients with ovarian cancer and the role of healthcare access, race, and ethnicity.
Gynecol Oncol. 2024;190:146-152.
PubMed Abstract available

FRICOVA L, Kommoss S, Scambia G, Ferron G, et al
Reproductive outcomes after fertility-sparing surgery for cervical cancer - results of the multicenter FERTISS study.
Gynecol Oncol. 2024;190:179-185.
PubMed Abstract available

QI C, Lyu M, Yao Z, Zhang F, et al
SVIL promotes ovarian cancer progression and epithelial-mesenchymal transition under hypoxic conditions through the TGF-beta/Smad pathway.
Gynecol Oncol. 2024;190:167-178.
PubMed Abstract available

CHUK E, Conway JL, Hanuschak J, Han K, et al
Patient-reported sexual health outcomes of cervical cancer patients treated with definitive chemoradiation and MRI-guided brachytherapy.
Gynecol Oncol. 2024;190:153-159.
PubMed Abstract available

KATO MK, Fujii E, Yamaguchi M, Higuchi D, et al
Excellent concordance of the molecular classification between preoperative biopsy and final hysterectomy in endometrial carcinoma.
Gynecol Oncol. 2024;190:139-145.
PubMed Abstract available

BARAKZAI SK, Bregar AJ, Del Carmen MG, Eisenhauer EL, et al
The association of maintenance hormone therapy with overall survival in advanced-stage low-grade serous ovarian carcinoma: A risk-set matched retrospective study.
Gynecol Oncol. 2024;190:119-123.
PubMed Abstract available

YUNOKAWA M, Kurihara N, Ishizuka N, Kanao H, et al
Investigating the timing and site of recurrence for ovarian clear cell carcinoma: Analysis of the JGOG/GCIG trial-JGOG 3017-A3.
Gynecol Oncol. 2024;190:113-118.
PubMed Abstract available

SKOF E, Stegel V, Dragos VS, Blatnik A, et al
Exploring the impact of BRCA1 and BRCA2 mutation type and location on Olaparib maintenance therapy in platinum-sensitive relapsed ovarian Cancer patients: A single center report.
Gynecol Oncol. 2024;190:104-112.
PubMed Abstract available

LEMIEUX M, Telles R, Goodheart M, Dahmoush L, et al
Quality of life and survivorship in patients with low-grade ovarian cancer.
Gynecol Oncol. 2024;190:96-103.
PubMed Abstract available

KOTSOPOULOS J, Lubinski J, Huzarski T, Bychkovsky BL, et al
Incidence of endometrial cancer in BRCA mutation carriers.
Gynecol Oncol. 2024;189:148-155.
PubMed Abstract available

WAGAR MK, Patel UJ, Bharucha K, Heisler CA, et al
Postoperative urinary retention by void trial methodology following radical hysterectomy for cervical cancer.
Gynecol Oncol. 2024;190:90-95.
PubMed Abstract available

GUERRA RA, Kaplan C, Borno H, Boscardin J, et al
The role of race/ethnicity and age in clinical trial knowledge among patients with gynecologic malignancy.
Gynecol Oncol. 2024;190:84-89.
PubMed Abstract available

SUZUKI Y, Chen L, Matsuo K, Ferris JS, et al
Weight-loss therapy in patients with obesity with endometrial intraepithelial neoplasia and uterine cancer.
Gynecol Oncol. 2024;190:78-83.
PubMed Abstract available

GAMBLE CR, Huang Y, Quinn J, Melamed A, et al
Neighborhood economic vulnerability as a predictor for patterns of care and outcomes for patients with uterine cancer.
Gynecol Oncol. 2024;190:70-77.
PubMed Abstract available

ROSS TL, Na R, Au-Yeung G, DeFazio A, et al
Are exercise and sitting time during chemotherapy for ovarian cancer associated with treatment-related side-effects, chemotherapy completion and survival?
Gynecol Oncol. 2024;190:53-61.
PubMed Abstract available

YOKOI A, Machida H, Shimada M, Mastuo K, et al
Efficacy and safety of minimally invasive surgery versus open laparotomy for epithelial ovarian cancer: A systematic review and meta-analysis.
Gynecol Oncol. 2024;190:42-52.
PubMed Abstract available

GU Y, Liu Y, Cheng H, Wang W, et al
Clinicopathological characteristics and oncologic outcomes of patients with gestational trophoblastic neoplasia manifesting as isolated pulmonary lesions.
Gynecol Oncol. 2024;190:28-34.
PubMed Abstract available

CUN HT, Bernard L, Lande KT, Lawson BC, et al
Comprehensive molecular characterization of early stage grade 3 endometrioid endometrial adenocarcinoma.
Gynecol Oncol. 2024;189:138-145.
PubMed Abstract available

FROEDING LP, Jensen PT
Commentary on "Simple versus radical hysterectomy in women with low-risk cervical cancer" by Plante M. et al. published in The New England Journal of Medicine.
Gynecol Oncol. 2024;189:137.
PubMed

OSTBY SA, Narasimhulu D, Ochs Kinney MA, Cliby W, et al
Defining optimal perioperative analgesia in patients undergoing laparotomy for advanced gynecologic malignancy: A randomized controlled trial.
Gynecol Oncol. 2024;190:11-17.
PubMed Abstract available

RIEDINGER CJ, Sakach J, Maples JM, Fulton J, et al
Glucagon-like peptide-1 (GLP-1) receptor agonists for weight management: A review for the gynecologic oncologist.
Gynecol Oncol. 2024;190:1-10.
PubMed Abstract available

HOLTZMAN S, Gellman C, Kaplowitz E, Barber E, et al
Yes, it's true: Benign hysterectomy trends for gynecologic oncologists in the United States from 2015 to 2021.
Gynecol Oncol. 2024;189:125-128.
PubMed Abstract available

CHELSEA NN, Posever N, Hsieh TYJ, Patterson S, et al
Implementation of a financial navigation program in gynecologic oncology.
Gynecol Oncol. 2024;189:119-124.
PubMed Abstract available

VAN DER EERDEN B, de Rooij BH, Schouten LJ, Boll D, et al
Quality of life among borderline ovarian tumor survivors: A comparison with survivors of early-stage ovarian cancer and a cancer-free population: A cross-sectional population-based PROFILES study.
Gynecol Oncol. 2024;189:111-118.
PubMed Abstract available

GLASER S, Han E
Optimizing and harmonizing lymph node dissection and radiotherapy in advanced vulvar cancer.
Gynecol Oncol. 2024;187:A1-A2.
PubMed

STROOT IAS, Bart J, Hollema H, Jalving M, et al
Long-term outcome of high-grade serous carcinoma established in risk-reducing salpingo-oophorectomy specimens in asymptomatic BRCA1/2 germline pathogenic variant carriers.
Gynecol Oncol. 2024;187:198-203.
PubMed Abstract available

WAGAR MK, Naik A, Zhang RC, Godecker A, et al
Incidence of postoperative venous thromboembolism in patients with vulvar carcinoma undergoing vulvectomy with or without lymphadenectomy.
Gynecol Oncol. 2024;187:192-197.
PubMed Abstract available

DEL VALLE D, Ruiz R, Lekuona A, Cobas P, et al
Superparamagnetic iron oxide (SPIO) for sentinel lymph node detection in vulvar cancer.
Gynecol Oncol. 2024;187:145-150.
PubMed Abstract available

VAN DEN BERG CB, Dasgupta S, Ewing-Graham PC, Bart J, et al
Does serous tubal intraepithelial carcinoma (STIC) metastasize? The clonal relationship between STIC and subsequent high-grade serous carcinoma in BRCA1/2 mutation carriers several years after risk-reducing salpingo-oophorectomy.
Gynecol Oncol. 2024;187:113-119.
PubMed Abstract available

ADOLPH L, Mann A, Liu XQ, Roberts L, et al
Follow-up of women with cervical adenocarcinoma in situ treated by conization: A single centre clinical experience.
Gynecol Oncol. 2024;187:74-79.
PubMed Abstract available

VUE NC, Sassani J, Prairie B, Yin Y, et al
Clinical outcomes with utilization of high-potency topical steroids in patients with lichen sclerosus-associated vulvar cancer.
Gynecol Oncol. 2024;187:58-63.
PubMed Abstract available

SWIFT BE, Khoja L, Matthews J, Croke J, et al
Management of inguinal lymph nodes in locally advanced, surgically unresectable, squamous cell carcinoma of the vulva.
Gynecol Oncol. 2024;187:46-50.
PubMed Abstract available

July 2024

DA COSTA AABA, Souza RP, Pandolfi NC, de Souza Castro F, et al
Should we consider progression-free survival benefits enough for drug approvals in locally advanced cervical cancer?
Gynecol Oncol. 2024;189:109-110.
PubMed

JOHANSEN G, Lampic C, Floter Radestad A, Dahm-Kahler P, et al
Health-related quality of life, sexual function, psychological health, reproductive concerns and fertility outcome in young women treated with fertility-sparing surgery for ovarian tumors - A prospective longitudinal multicentre study.
Gynecol Oncol. 2024;189:101-108.
PubMed Abstract available

ZANNONI GF, Santoro A, Arciuolo D, Travaglino A, et al
Endometrial cancer and 2023 FIGO staging system: Not too soon, but maybe too much?
Gynecol Oncol. 2024;189:98-100.
PubMed

GUPTA A, O'Cearbhaill RE, Block MS, Hamilton E, et al
Vaccination with folate receptor-alpha peptides in patients with ovarian cancer following response to platinum-based therapy: A randomized, multicenter clinical trial.
Gynecol Oncol. 2024;189:90-97.
PubMed Abstract available

SULLIVAN MW, Kanbergs AN, Growdon WB
Letter to the Editor: Referring to the manuscript entitled "Surgical nodal assessment for endometrial hyperplasia - A meta-analysis and systematic review" recently reported from Nahshon et al. (Gynecol Oncol., 188;140-146;2024).
Gynecol Oncol. 2024;189:88-89.
PubMed

HUEPENBECKER SP, Soliman PT, Meyer LA, Iniesta MD, et al
Perioperative outcomes in gynecologic pelvic exenteration before and after implementation of an enhanced recovery after surgery program.
Gynecol Oncol. 2024;189:80-87.
PubMed Abstract available

FINCH L, Broach V, Feinberg J, Al-Niaimi A, et al
ChatGPT compared to national guidelines for management of ovarian cancer: Did ChatGPT get it right? - A Memorial Sloan Kettering Cancer Center Team Ovary study.
Gynecol Oncol. 2024;189:75-79.
PubMed Abstract available

LEE YW, Wang V, Wang MJ, Kim KH, et al
The effects of Asian American Pacific Islander (AAPI) data inequities in gynecologic oncology.
Gynecol Oncol. 2024;189:64-67.
PubMed Abstract available

KAMRAVA MR, Gonzalez-Martin A, Pothuri B, Vergote I, et al
Patterns of initial ovarian cancer recurrence on niraparib maintenance monotherapy in patients with no baseline evidence of disease after first-line chemotherapy: An ad hoc subgroup analysis of PRIMA/ENGOT-OV26/GOG-3012.
Gynecol Oncol. 2024;189:68-74.
PubMed Abstract available

CABRERA S, Bebia V, Lopez-Gil C, Luzarraga-Aznar A, et al
Molecular classification improves preoperative risk assessment of endometrial cancer.
Gynecol Oncol. 2024;189:56-63.
PubMed Abstract available

BERGSTEIN A, Huang Y, Hershman DL, Xu X, et al
Impact of medicaid expansion on cervical cancer screening: A state-specific difference in difference analysis.
Gynecol Oncol. 2024;189:49-55.
PubMed Abstract available

SENGUTTUVAN RN, Lugo-Santiago N, Nakamura B, Song M, et al
Uterine cancer restaging according to the updated 2023 FIGO Guidelines does not uniformly affect prognosis: An institutional retrospective cohort study.
Gynecol Oncol. 2024;189:41-48.
PubMed Abstract available

POLAN RM, Ali-Fehmi R, Grace AK, Mattei LH, et al
Occult residual ovarian tissue at the time of minimally invasive risk reducing surgery in women with BRCA mutations.
Gynecol Oncol. 2024;189:37-40.
PubMed Abstract available

ANDRES S, Finch L, Iasonos A, Zhou Q, et al
Basket study of oral progesterone antagonist onapristone extended release in progesterone receptor-positive recurrent granulosa cell, low-grade serous ovarian cancer, or endometrioid endometrial cancer.
Gynecol Oncol. 2024;189:30-36.
PubMed Abstract available

MAHONEY DE, Mukherjee R, Thompson J
Elucidating the influences of social determinants of health on perceived overall health among African American/Black and Hispanic ovarian cancer survivors using the NIH All of Us Research Program.
Gynecol Oncol. 2024;189:24-29.
PubMed Abstract available

MCNAMARA B, Greenman M, Bellone S, Santin LA, et al
Preclinical activity of datopotamab deruxtecan, a novel TROP2 directed antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (TROP2) in ovarian carcinoma.
Gynecol Oncol. 2024;189:16-23.
PubMed Abstract available

ARO K, Pasanen A, Butzow R, Loukovaara M, et al
The impact of estrogen receptor and L1 cell adhesion molecule expression on endometrial cancer outcome correlates with clinicopathological risk group and molecular subgroup.
Gynecol Oncol. 2024;189:9-15.
PubMed Abstract available

GRAHAM O, Rodriguez J, Abbott R, Lomonosova E, et al
A toolkit for a modern gynecologic oncology tissue bank.
Gynecol Oncol. 2024;189:1-8.
PubMed Abstract available

EZENDAM NPM, de Rooij BH, Creutzberg CL, Kruitwagen RFPM, et al
Effect of reduced follow-up care on patient satisfaction with care among patients with endometrial cancer: The ENSURE randomized controlled trial.
Gynecol Oncol. 2024;188:169-183.
PubMed Abstract available

KUMAR PP, Smith D, Key J, Dong H, et al
Preclinical 3D model screening reveals digoxin as an effective therapy for a rare and aggressive type of endometrial cancer.
Gynecol Oncol. 2024;188:162-168.
PubMed Abstract available

SHALOWITZ DI, Rajczi A
Refining research on access to gynecologic cancer care: The DIMeS framework.
Gynecol Oncol. 2024;188:158-161.
PubMed Abstract available

CROWLEY F, Broderick S, Francis JH, O'Cearbhaill RE, et al
Ocular side effects of anticancer agents used in the treatment of gynecologic cancers.
Gynecol Oncol. 2024;188:147-157.
PubMed Abstract available

NAHSHON C, Leitao MM Jr, Lavie O, Schmidt M, et al
Surgical nodal assessment for endometrial hyperplasia - A meta-analysis and systematic review.
Gynecol Oncol. 2024;188:140-146.
PubMed Abstract available

STEWART KT, Jafari H, Pattillo J, Santos J, et al
Avoiding the needle: A quality improvement program introducing apixaban for extended thromboprophylaxis after major gynecologic cancer surgery.
Gynecol Oncol. 2024;188:131-139.
PubMed Abstract available

RODRIGUEZ GC, Yozwiak M, Nelson OL, Zhang HH, et al
The karyometric signature is altered in fallopian tubes with serous tubal intraepithelial carcinoma.
Gynecol Oncol. 2024;186:110-116.
PubMed Abstract available

June 2024

FUMAGALLI D, Sonik R, De Vitis LA, Rossi V, et al
Evaluating nutrition in advanced ovarian cancer: which biomarker works best?
Gynecol Oncol. 2024;188:97-102.
PubMed Abstract available

MEADE CE, Sinnott JA, Backes FJ, Cosgrove CM, et al
Associations between race and ethnicity and treatment setting among gynecologic cancer patients.
Gynecol Oncol. 2024;188:111-119.
PubMed Abstract available

MIRZA MR, Tandaric L, Henriksen JR, Maenpaa J, et al
NSGO-OV-UMB1/ENGOT-OV30: A phase II study of durvalumab in combination with the anti-CD73 monoclonal antibody Oleclumab in patients with relapsed ovarian cancer.
Gynecol Oncol. 2024;188:103-110.
PubMed Abstract available

KA K, Cordoba A, Cagetti LV, Schiappa R, et al
Preoperative brachytherapy of early-stage cervical cancer: A multicenter study by the SFRO brachytherapy group.
Gynecol Oncol. 2024;188:90-96.
PubMed Abstract available

KOCIAN R, Kohler C, Bajsova S, Jarkovsky J, et al
Sentinel lymph node pathological ultrastaging: Final outcome of the Sentix prospective international study in patients with early-stage cervical cancer.
Gynecol Oncol. 2024;188:83-89.
PubMed Abstract available

MANNING-GEIST BL, Sullivan MW, Zhou Q, Iasonos A, et al
Folate receptor alpha expression in low-grade serous ovarian cancer: Exploring new therapeutic possibilities.
Gynecol Oncol. 2024;188:52-57.
PubMed Abstract available

KOH B, Ryu JY, Noh JJ, Hwang JR, et al
Anti-cancer effects of benzimidazole derivative BNZ-111 on paclitaxel-resistant ovarian cancer.
Gynecol Oncol. 2024;188:60-70.
PubMed Abstract available

EKMANN-GADE AW, Hogdall CK, Seibaek L, Noer MC, et al
Corrigendum to "Incidence, treatment, and survival trends in older versus younger women with epithelial ovarian cancer from 2005 to 2018: A nationwide Danish study" [Gynecologic Oncology 164/1(2022) 120-128].
Gynecol Oncol. 2024;188:58-59.
PubMed

BHATNAGAR AR, Ghanem AI, Alkamachi B, Allo G, et al
The prognostic impact of substantial lymphovascular space invasion in women with node negative FIGO stage I uterine carcinoma.
Gynecol Oncol. 2024;188:44-51.
PubMed Abstract available

GARZON S, Calio A, Ferrari FA, Iannicello CQ, et al
Uterine perivascular epithelioid cell tumors (PEComa) and the accuracy of proposed classification systems in predicting the malignant versus non-malignant behavior.
Gynecol Oncol. 2024;188:35-43.
PubMed Abstract available

CHEN H, Chen Y, Zheng A, Tan X, et al
Is pharmacologic venous Thromboprophylaxis necessary for patients undergoing minimally invasive surgery for endometrial Cancer? A systematic review and Meta-analysis.
Gynecol Oncol. 2024;188:27-34.
PubMed Abstract available

WALKER CA, Edwards C, McIntire D, Makepeace L, et al
Predicting VTE and utility of thromboprophylaxis in metastatic and recurrent cervical cancer.
Gynecol Oncol. 2024;188:22-26.
PubMed Abstract available

PATEL KB, Escamilla V, Wolfe L, Morris T, et al
Food deserts, endometrial cancer survivors, and healthy food access: Is it equitable in rural America? - A geospatial analysis.
Gynecol Oncol. 2024;188:8-12.
PubMed Abstract available

FLANIGAN MR, Bell SG, Donovan HS, Zhao J, et al
Variables impacting prolonged post-anesthesia care unit length of stay in gynecologic cancer patients in the era of same day minimally invasive hysterectomy.
Gynecol Oncol. 2024;186:211-215.
PubMed Abstract available

BORHO L, Bao R, Elishaev E, Dinkins KD, et al
Association of allostatic load with overall survival in epithelial ovarian cancer.
Gynecol Oncol. 2024;186:204-210.
PubMed Abstract available

CHAN JK, Tewari K, Monk BJ, Herzog TJ, et al
Biomarker guidance in selection among breakthrough treatment options in advanced and recurrent endometrial cancer.
Gynecol Oncol. 2024;187:249-252.
PubMed

MAKKER V, Perez-Fidalgo JA, Valabrega G, Hamilton E, et al
Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study.
Gynecol Oncol. 2024 Jun 3:S0090-8258(24)00234.
PubMed Abstract available

AISAGBONHI O, Ghlichloo I, Hong DS, Roma A, et al
Comprehensive next-generation sequencing identifies novel putative pathogenic or likely pathogenic germline variants in patients with concurrent tubo-ovarian and endometrial serous and endometrioid carcinomas or precursors.
Gynecol Oncol. 2024;187:241-248.
PubMed Abstract available

VALABREGA G, Pothuri B, Oaknin A, Graybill WS, et al
Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
Gynecol Oncol. 2024;187:128-138.
PubMed Abstract available

O'CONNOR RM, Huang DS, Rimel BJ, Kim KH, et al
Unmet financial needs among patients crowdfunding to support gynecologic cancer care.
Gynecol Oncol. 2024;186:199-203.
PubMed Abstract available

BERTON D, Pautier P, Lorusso D, Gennigens C, et al
Antitumor activity and safety of the PD-1 inhibitor retifanlimab in patients with recurrent microsatellite instability-high or deficient mismatch repair endometrial cancer: Final safety and efficacy results from cohort H of the POD1UM-101 phase I stud
Gynecol Oncol. 2024;186:191-198.
PubMed Abstract available

CHALIF J, Kistenfeger Q, Fulton J, Morton M, et al
Diagnosis and management of gastric-type endocervical adenocarcinoma: A case report and review of the literature.
Gynecol Oncol. 2024;185:165-172.
PubMed Abstract available

SCALISE CB, Kincaid K, Thigpen H, Moore J, et al
A spatial proteomic study of platinum refractory HGSOC implicates dual AKT and WNT activity linked to an immunosuppressive tumor microenvironment.
Gynecol Oncol. 2024;185:83-94.
PubMed Abstract available

FEINBERG J, Da Cruz Paula A, da Silva EM, Pareja F, et al
Adenoid cystic carcinoma of the Bartholin's gland is underpinned by MYB- and MYBL1- rearrangements.
Gynecol Oncol. 2024;185:58-67.
PubMed Abstract available

HOHN AK, Forberger M, Alfaraidi M, Gilks CB, et al
High concordance of molecular subtyping between pre-surgical biopsy and surgical resection specimen (matched-pair analysis) in patients with vulvar squamous cell carcinoma using p16- and p53-immunostaining.
Gynecol Oncol. 2024;185:17-24.
PubMed Abstract available

May 2024

FRANCO S, Godley LA
Myeloid neoplasms in individuals with breast and ovarian cancer and the association with deleterious germline variants.
Gynecol Oncol. 2024;187:235-240.
PubMed Abstract available

LOF P, van Soolingen NJ, Piek JMJ, Aarts JWM, et al
Preferences and considerations for interval cytoreductive surgery in advanced ovarian cancer: The patient's perspective.
Gynecol Oncol. 2024;187:227-234.
PubMed Abstract available

PITIYARACHCHI O, Ansell PJ, Coleman RL, Dinh MH, et al
Homologous recombination deficiency should be tested for in patients with advanced stage high-grade serous ovarian cancer aged 70 years and over.
Gynecol Oncol. 2024;187:221-226.
PubMed Abstract available

YUAN G, Zhang K, Zheng H, Wu Y, et al
Suvemcitug plus chemotherapy for platinum-resistant epithelial ovarian, fallopian tube and primary peritoneal cancer: A phase 1b dose-escalation trial.
Gynecol Oncol. 2024;187:212-220.
PubMed Abstract available

CARBALLO EV, Kim KH, Penn CA
Trends in estimated PARP inhibitor eligibility and benefit among US epithelial ovarian cancer patients.
Gynecol Oncol. 2024;187:204-211.
PubMed Abstract available

OSAZUWA-PETERS OL, Greiner MA, Kaufman BG, Zambrano Guevara LM, et al
ACO leakage among gynecologic cancer patients: Incidence, predictors, and impact on annual Medicare expenditure.
Gynecol Oncol. 2024;187:184-191.
PubMed Abstract available

PERSSON J, Luhrs O, Geppert B, Ekdahl L, et al
A prospective study evaluating an optimized sentinel node algorithm in early stage cervical cancer: The PROSACC-study.
Gynecol Oncol. 2024;187:178-183.
PubMed Abstract available

MARCHETTI C, Ataseven B, Perrone AM, Cassani C, et al
Clinical characteristics and survival outcome of early-stage, high-grade, serous tubo-ovarian carcinoma according to BRCA mutational status.
Gynecol Oncol. 2024;187:170-177.
PubMed Abstract available

LARAJA A, Connor Y, Poulson MR
The effect of urban racial residential segregation on ovarian cancer diagnosis, treatment, and survival.
Gynecol Oncol. 2024;187:163-169.
PubMed Abstract available

FERRIS JS, Prest MT, Hur C, Chen L, et al
Trends in uterine cancer incidence in the United States: The contribution of age, period and cohort effects.
Gynecol Oncol. 2024;187:151-162.
PubMed Abstract available

ZENATRI M, Perennec T, Michon C, Gernier F, et al
Pharmacogenomic predictor of long-term residual chemotherapy-induced peripheral neuropathy in ovarian cancer survivors: A substudy of the GINECO Vivrovaire study.
Gynecol Oncol. 2024;187:139-144.
PubMed Abstract available

HUNSBERGER KS, Treiman S, Monk BJ, Tewari KS, et al
A systematic review of stage IVA cervical cancer treatment: Challenges in the management of an understudied group.
Gynecol Oncol. 2024;187:120-127.
PubMed Abstract available

LIU JF, Xiong N, Wenham RM, Wahner-Hendrickson A, et al
A phase 2 trial exploring the significance of homologous recombination status in patients with platinum sensitive or platinum resistant relapsed ovarian cancer receiving combination cediranib and olaparib.
Gynecol Oncol. 2024;187:105-112.
PubMed Abstract available

ROSATI A, De Rose AM, Gallotta V, Giannarelli D, et al
Feasibility and operative outcomes of surgery in the liver area in advanced ovarian cancer.
Gynecol Oncol. 2024;187:98-104.
PubMed Abstract available

PIEDIMONTE S, Murray C, Atenafu EG, Rouzbahman M, et al
Correlating the KELIM (CA125 elimination rate constant K) score and the chemo-response score as predictors of chemosensitivity in patients with advanced ovarian carcinoma.
Gynecol Oncol. 2024;187:92-97.
PubMed Abstract available

KIM JH, Han KH, Park EY, Kim ET, et al
Efficacy of immune-checkpoint inhibitors combined with cytotoxic chemotherapy in advanced or recurrent endometrial cancer: A systematic review and meta-analysis.
Gynecol Oncol. 2024;187:85-91.
PubMed Abstract available

FILIPPOVA OT, Boecking K, Broach V, Gardner GJ, et al
Trends in specific procedures performed at the time of cytoreduction for ovarian cancer: Is interval debulking surgery truly less radical? A Memorial Sloan Kettering Cancer Center Team Ovary study.
Gynecol Oncol. 2024;187:80-84.
PubMed Abstract available

LIANG S, Ge H, Zhou S, Tang J, et al
Prognostic factors of 87 ovarian yolk sac tumor (OYST) patients and molecular characteristics of persistent and recurrent OYST.
Gynecol Oncol. 2024;187:64-73.
PubMed Abstract available

CHIBA Y, Kojima Y, Yazaki S, Yoshida H, et al
Trop-2 expression and the tumor immune microenvironment in cervical cancer.
Gynecol Oncol. 2024;187:51-57.
PubMed Abstract available

GONZALEZ-MARTIN A, Chung HC, Saada-Bouzid E, Yanez E, et al
Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study.
Gynecol Oncol. 2024;186:182-190.
PubMed Abstract available

MATSUO K, Chen L, Klar M, Lee MW, et al
Prognostic performance of the 2023 FIGO staging schema for endometrial cancer.
Gynecol Oncol. 2024;187:37-45.
PubMed Abstract available

MITRIC C, Sayyid RK, Fleshner NE, Look Hong NJ, et al
Hysterectomy versus chemotherapy for low-risk non-metastatic gestational trophoblastic neoplasia (GTN): A cost-effectiveness analysis.
Gynecol Oncol. 2024;187:30-36.
PubMed Abstract available

PAPPAS TC, Roy Choudhury M, Chacko BK, Twiggs LB, et al
Neural network-derived multivariate index assay demonstrates effective clinical performance in longitudinal monitoring of ovarian cancer risk.
Gynecol Oncol. 2024;187:21-29.
PubMed Abstract available

DEMIRKIRAN C, Greenman M, Bellone S, McNamara B, et al
Preclinical in vitro and in vivo activity of the RAF/MEK clamp avutometinib in combination with FAK inhibition in uterine carcinosarcomas.
Gynecol Oncol. 2024;187:12-20.
PubMed Abstract available

RING KL, Duska LR
How far is too far? Cancer prevention and clinical trial enrollment in geographically underserved patient populations.
Gynecol Oncol. 2024;184:8-15.
PubMed Abstract available

MACCHIA G, Cilla S, Pezzulla D, Campitelli M, et al
Efficacy of stereotactic body radiotherapy and response prediction using artificial intelligence in oligometastatic gynaecologic cancer.
Gynecol Oncol. 2024;184:16-23.
PubMed Abstract available

April 2024

HOLTZMAN S, McCarthy L, Estevez SL, Lee JA, et al
Walking the tightrope: Fertility preservation among hereditary breast and ovarian Cancer syndrome Previvors.
Gynecol Oncol. 2024;186:176-181.
PubMed Abstract available

JIANG Z, Zhu M, Zhang L, Cui H, et al
Antitumor immunity and prognosis value elicited by FAT3 and LRP1B co-mutation in endometrial cancer.
Gynecol Oncol. 2024;187:1-11.
PubMed Abstract available

HOFFMAN M, Dunsmore V, Cliby W, Chi D, et al
Surgical training of gynecologic oncology fellows: Long-term trends and implications for future education.
Gynecol Oncol. 2024;184:254-258.
PubMed Abstract available

SMITH AJB, O'Brien C, Haggerty A, Ko EM, et al
"Having cancer is very expensive": A qualitative study of patients with ovarian cancer and PARP inhibitor treatment.
Gynecol Oncol. 2024;186:170-175.
PubMed Abstract available

CHALIF J, Chambers LM, Yao M, Kuznicki M, et al
Extended-duration antibiotics are not associated with a reduction in surgical site infection in patients with ovarian cancer undergoing cytoreductive surgery with large bowel resection.
Gynecol Oncol. 2024;186:161-169.
PubMed Abstract available

PENG H, Jiang J, Li L, Hao Z, et al
Mismatch repair deficiency and abnormal p53 expression has significant predictive value for progesterone resistance and endometrial tumorigenesis in patients with endometrial atypical hyperplasia receiving fertility-preserving treatment.
Gynecol Oncol. 2024;186:154-160.
PubMed Abstract available

ALGERA MD, van Driel WJ, Slangen BFM, Wouters MWJM, et al
Effect of surgical volume on short-term outcomes of cytoreductive surgery for advanced-stage ovarian cancer: A population-based study from the Dutch Gynecological Oncology Audit.
Gynecol Oncol. 2024;186:144-153.
PubMed Abstract available

PATEL JM, Hermann CE, Growdon WB, Aviki E, et al
ChatGPT accurately performs genetic counseling for gynecologic cancers.
Gynecol Oncol. 2024;183:115-119.
PubMed Abstract available

WANG CC, Grubbs A, Foley OW, Bharadwa S, et al
The activity advantage: Objective measurement of preoperative activity is associated with postoperative recovery and outcomes in patients undergoing surgery with gynecologic oncologists.
Gynecol Oncol. 2024;186:137-143.
PubMed Abstract available

ZHAO Z, Wang J, Kong W, Fang Z, et al
Intermittent energy restriction inhibits tumor growth and enhances paclitaxel response in a transgenic mouse model of endometrial cancer.
Gynecol Oncol. 2024;186:126-136.
PubMed Abstract available

NELSON AT, Harris AK, Watson D, Kamihara J, et al
Outcomes in ovarian Sertoli-Leydig cell tumor: A report from the International Pleuropulmonary Blastoma/DICER1 and Ovarian and Testicular Stromal Tumor Registries.
Gynecol Oncol. 2024;186:117-125.
PubMed Abstract available

EHMANN S, Lam C, Zhou Q, Iasonos A, et al
Secondary cytoreductive surgery and oncologic outcomes in the era of targeted maintenance therapy for recurrent, platinum-sensitive ovarian cancer.
Gynecol Oncol. 2024;186:104-109.
PubMed Abstract available

ESPINOSA I, D'Angelo E, Prat J
Endometrial carcinoma: 10 years of TCGA (the cancer genome atlas): A critical reappraisal with comments on FIGO 2023 staging.
Gynecol Oncol. 2024;186:94-103.
PubMed Abstract available

MATSUO K, Huang Y, Matsuzaki S, Vallejo A, et al
Cesarean hysterectomy for placenta accreta spectrum: Surgeon specialty-specific assessment.
Gynecol Oncol. 2024;186:85-93.
PubMed Abstract available

GITTO SB, Ihewulezi CJN, Powell DJ Jr
Adoptive T cell therapy for ovarian cancer.
Gynecol Oncol. 2024;186:77-84.
PubMed Abstract available

DAHM-KAHLER P, Radestad AF, Holmberg E, Borgfeldt C, et al
Has time to chemotherapy from primary debulking surgery in advanced ovarian cancer an impact on survival? - A population-based nationwide SweGCG study.
Gynecol Oncol. 2024;186:69-76.
PubMed Abstract available

GIEN LT, Enserro DM, Block MS, Waggoner S, et al
Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016.
Gynecol Oncol. 2024;186:61-68.
PubMed Abstract available

SAYLOR KW, Fernandes EQ, Adams M, Paraghamian S, et al
Predictors of germline genetic testing referral and completion in ovarian cancer patients at a Comprehensive Cancer Center.
Gynecol Oncol. 2024;186:53-60.
PubMed Abstract available

KOPELMAN ZA, Tian C, Tumas J, Phippen NT, et al
Disease progression, survival, and molecular disparities in Black and White patients with endometrioid endometrial carcinoma in real-world registries and GOG/NRG oncology randomized phase III clinical trials.
Gynecol Oncol. 2024;183:103-114.
PubMed Abstract available

HOLLIS RL, Elliott R, Dawson JC, Ilenkovan N, et al
High throughput screening identifies dasatinib as synergistic with trametinib in low grade serous ovarian carcinoma.
Gynecol Oncol. 2024;186:42-52.
PubMed Abstract available

VESZTERGOM D, Teglas G, Bahrehmand K, Torok A, et al
Reducing radicality in fertility-sparing surgery is associated with improved in vitro fertilization outcome in early-stage cervical cancer: A national retrospective study.
Gynecol Oncol. 2024;186:35-41.
PubMed Abstract available

Introduction to SGO VSI.
Gynecol Oncol. 2024;183:A7.
PubMed

RIEDINGER CJ, Barrington DA, Nagel CI, Khadraoui WK, et al
Retraction notice to "Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent endometrial cancer" [Gynecologic Oncology 183 (2024) 78-84].
Gynecol Oncol. 2024;183:R1.
PubMed

March 2024

MONTEMORANO L, Shultz ZB, Farooque A, Hyun M, et al
TP53 mutations and the association with platinum resistance in high grade serous ovarian carcinoma.
Gynecol Oncol. 2024;186:26-34.
PubMed Abstract available

SHEN X, Wang J, Deng B, Chen S, et al
High-dose ascorbate exerts anti-tumor activities and improves inhibitory effect of carboplatin through the pro-oxidant function pathway in uterine serous carcinoma cell lines.
Gynecol Oncol. 2024;183:93-102.
PubMed Abstract available

SALINARO JR, Rossi EC, Penvose KN, Zhang Y, et al
Delayed publication of clinical trials in gynecologic oncology.
Gynecol Oncol. 2024;183:74-77.
PubMed Abstract available

HUANG Y, Rauh-Hain JA, McCoy TH, Hou JY, et al
Comparing survival of older ovarian cancer patients treated with neoadjuvant chemotherapy versus primary cytoreductive surgery: Reducing bias through machine learning.
Gynecol Oncol. 2024;186:9-16.
PubMed Abstract available

DESRAVINES N, Hazimeh D, Desjardins MR, Wethington SL, et al
Healthcare utilization in women diagnosed with endometrial cancer: A survey-based study.
Gynecol Oncol. 2024;186:1-8.
PubMed Abstract available

WILLIAMS-BROWN MY, Summey RM, Newtson A, Burke W, et al
System-level recommendations for improved wellness for gynecologic oncologists: A Society of Gynecologic Oncology Review.
Gynecol Oncol. 2024;183:85-92.
PubMed Abstract available

RIEDINGER CJ, Barrington DA, Nagel CI, Khadraoui WK, et al
Cost-effectiveness of chemotherapy and dostarlimab for advanced or recurrent endometrial cancer.
Gynecol Oncol. 2024;183:78-84.
PubMed Abstract available

KIM NK, Choi CH, Seong SJ, Lee JM, et al
Treatment outcomes according to various progestin treatment strategies in patients with atypical hyperplasia/endometrial intraepithelial neoplasia - Multicenter retrospective study (KGOG2033).
Gynecol Oncol. 2024;183:68-73.
PubMed Abstract available

PASSARELLI A, Carbone V, Pignata S, Mazzeo R, et al
Alpelisib for PIK3CA-mutated advanced gynecological cancers: First clues of clinical activity.
Gynecol Oncol. 2024;183:61-67.
PubMed Abstract available

LIANG MI, Dholakia JD, Lee GM, Wang L, et al
Dedicated financial hardship screening adds value to routine distress screening among gynecologic cancer patients.
Gynecol Oncol. 2024;183:53-60.
PubMed Abstract available

AHSAN MD, Webster EM, Wolfe IA, McGonigle R, et al
Personalized survivorship care: Routine breast cancer risk assessment in the gynecologic oncology clinic.
Gynecol Oncol. 2024;183:47-52.
PubMed Abstract available

HARTMAN YAW, Kenkhuis MF, Stelten S, Brouwer CG, et al
Demographic, clinical, and sociocognitive determinants related to physical activity and dietary intake in patients with ovarian cancer: A cross-sectional study.
Gynecol Oncol. 2024;183:39-46.
PubMed Abstract available

LEVINE BJ
Letter re: Ban et al., A personalized probabilistic approach to ovarian cancer diagnostics.
Gynecol Oncol. 2024 Mar 15:S0090-8258(24)00155.
PubMed

ROSS DH, Gomez K, Harmon G, Mysz ML, et al
Evaluating outcomes and toxicities for a newly implemented MRI-based brachytherapy program for cervical cancer.
Gynecol Oncol. 2024;183:33-38.
PubMed Abstract available

CACCIOTTOLA L, Camboni A, Gatti E, Marbaix E, et al
Fertility potential and safety assessment of residual ovarian cortex in young women diagnosed with epithelial borderline and early-stage malignant ovarian tumors.
Gynecol Oncol. 2024;183:15-24.
PubMed Abstract available

BYRNE M, Sia TY, Fong C, Khurram A, et al
Mainstreaming in parallel with ovarian cancer tumor testing to improve genetic testing uptake.
Gynecol Oncol. 2024 Mar 14:S0090-8258(24)00144.
PubMed Abstract available

GASS P, Thiel FC, Haberle L, Ackermann S, et al
Primary results of the AGO-Zervix-1 Study: A prospective, randomized phase III study to compare the effects of paclitaxel and topotecan with those of cisplatin and topotecan in the treatment of patients with recurrent and persistent cervical cancer.
Gynecol Oncol. 2024;183:25-32.
PubMed Abstract available

BJERRE TRENT PK, Nordskar NJ, Wangen KR, Engeskaug MI, et al
Corrigendum to "Self-reported lower extremity lymphedema and quality of life after surgical staging of endometrial carcinoma: A population based cross-sectional study" [Gynecologic Oncology 175 (2023) 72-80].
Gynecol Oncol. 2024;183:7-8.
PubMed

GLASER GE, Maddy B, Kumar A, Ishitani K, et al
Impact of pharmacogenomic profiles on post-surgical pain following laparotomy for gynecologic pathology.
Gynecol Oncol. 2024;183:9-14.
PubMed Abstract available

PANDYA D, Tomita S, Rhenals MP, Swierczek S, et al
Mutations in cancer-relevant genes are ubiquitous in histologically normal endometrial tissue.
Gynecol Oncol. 2024;185:194-201.
PubMed Abstract available

GAFFNEY D, Matias-Guiu X, Mutch D, Scambia G, et al
2023 FIGO staging system for endometrial cancer: The evolution of the revolution.
Gynecol Oncol. 2024;184:245-253.
PubMed Abstract available

RICHARDSON DL, Moore KN, Vergote I, Gilbert L, et al
Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRalpha)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer.
Gynecol Oncol. 2024;185:186-193.
PubMed Abstract available

NOGUEIRA-RODRIGUES A, Giannecchini GV, Secord AA
Real world challenges and disparities in the systemic treatment of ovarian cancer.
Gynecol Oncol. 2024;185:180-185.
PubMed Abstract available

OLAWAIYE AB
2023 FIGO staging for endometrial cancer, a look at both sides of the coin.
Gynecol Oncol. 2024;184:243-244.
PubMed

EJAREDAR M, Ruzycki SM, Glazer TS, Trudeau P, et al
Implementation of a surgical site infection prevention bundle in gynecologic oncology patients: An enhanced recovery after surgery initiative.
Gynecol Oncol. 2024;185:173-179.
PubMed Abstract available

GLASER GE, Dowdy SC
Sentinel lymph node biopsy in high-risk endometrial cancer: The denouement.
Gynecol Oncol. 2024;182:A1-A2.
PubMed

CHEN W, Xie J, Gao C, Zhang C, et al
Hypertension associated with niraparib in cancer patients: A pharmacovigilance analysis based on the FAERS database and meta-analysis of randomized controlled trials.
Gynecol Oncol. 2024;182:108-114.
PubMed Abstract available

February 2024

CAO B, Li Y, Liu Y, Chen X, et al
A multi-center study to predict the risk of intraoperative hypothermia in gynecological surgery patients using preoperative variables.
Gynecol Oncol. 2024;185:156-164.
PubMed Abstract available

CHEN Y, Yang J, Wan Y, Li Q, et al
DEAR model in overweight endometrial cancer patients undergoing fertility-sparing treatment: A randomized controlled trial.
Gynecol Oncol. 2024;185:148-155.
PubMed Abstract available

COSTALES AB, Crane EK, Chambers L, Yao M, et al
Laparoscopic predictability of minimally invasive interval debulking in advanced ovarian cancer: The MIID-SOC trial.
Gynecol Oncol. 2024;185:143-147.
PubMed Abstract available

SALMAN L, Covens A, Vicus D, Podolsky S, et al
The role of surgeon specialty in management and survival of malignant ovarian germ cell tumors: A population-based study.
Gynecol Oncol. 2024;185:138-142.
PubMed Abstract available

RONCOLATO F, King MT, O'Connell RL, Lee YC, et al
Hidden in plain sight - Survival consequences of baseline symptom burden in women with recurrent ovarian cancer.
Gynecol Oncol. 2024;185:128-137.
PubMed Abstract available

AGUSTI N, Kanbergs A, Nitecki R
Potential of molecular classification to guide fertility-sparing management among young patients with endometrial cancer.
Gynecol Oncol. 2024;185:121-127.
PubMed Abstract available

MCNAMARA B, Demirkiran C, Hartwich TMP, Bellone S, et al
Preclinical efficacy of RAF/MEK clamp avutometinib in combination with FAK inhibition in low grade serous ovarian cancer.
Gynecol Oncol. 2024 Feb 9:S0090-8258(24)00043.
PubMed Abstract available

APPLEBAUM AJ
The importance of family-focused care in the setting of advanced gynecological cancers.
Gynecol Oncol. 2024;181:A1-A2.
PubMed

PELTECU G
Eugen Bogdan Aburel, a pioneer of fertility sparing surgery.
Gynecol Oncol. 2024;181:40-45.
PubMed Abstract available

VASTA FM, Cormio G, Cassani C, Bergamini A, et al
Reproductive outcomes after conservative treatment in early and advanced stage MOGCTs.
Gynecol Oncol. 2024;181:28-32.
PubMed Abstract available

TAYLOR DD, Gercel-Taylor C, Parker LP
Retraction notice to "Patient-derived tumor reactive antibodies as diagnostic markers for ovarian cancer" [Gynecologic Oncology 115 (2009) 112-120].
Gynecol Oncol. 2024;181:186.
PubMed

January 2024

FADER AN, Ko EM, Pollock BD, Blank SV, et al
An SGO commentary: U.S. News and World Report gynecologic oncology procedural ratings-Do they reflect high-quality care?
Gynecol Oncol. 2024 Jan 25:S0090-8258(24)00002.
PubMed Abstract available

October 2023

KIM JH, Kim SI, Park EY, Ha HI, et al
Impact of postoperative residual disease on survival in epithelial ovarian cancer with consideration of recent frontline treatment advances: A systematic review and meta-analysis.
Gynecol Oncol. 2023;179:24-32.
PubMed Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Gynecology is free of charge.